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ABSTRACT
REGULATION OF THE GLUTAMATE/GLUTAMINE CYCLE BY NITRIC OXIDE IN THE
CENTRAL NERVOUS SYSTEM
Karthik Anderson Raju
Harry Ischiropoulos

Nitric oxide (˙NO) is a critical contributor to glutamatergic neurotransmission in the central
nervous system (CNS). Much of its influence is due to the ability of this molecule to regulate
protein structure and function through its posttranslational modification of cysteine residues, a
process known as S-nitrosylation. However, little is known about the extent of this modification
and its associated functional effects in the brain under physiological conditions. We employed
mass spectrometry (MS)-based methodologies to interrogate the S-nitrosocysteine proteome in
wild-type (WT), neuronal nitric oxide synthase-deficient (nNOS-/-), and endothelial nitric oxide
synthase-deficient (eNOS-/-) mouse brain. These approaches identified 269 sites from 136
proteins in the WT brain, with notable reductions in the number of sites detected in either eNOS-/(50% of WT) or nNOS-/- brain (26% of WT). Gene ontology analysis revealed a cluster of Snitrosylated proteins participating in the glutamate/glutamine cycle in wild-type and eNOS-/- mice
that was underrepresented in nNOS-/- animals, suggesting a role for nNOS-derived ˙NO in the
regulation of glutamate utilization in the CNS. Functional profiling of this pathway using 15Nglutamine based metabolomic analyses and enzymatic activity assays uncovered decreased
conversion of glutamate to glutamine and increased glutamate oxidation in nNOS-/- mice relative
to the other genotypes. Furthermore, site-directed mutagenesis of the rat sodium-dependent
excitatory amino acid transporter 2 at Cys373 and Cys562 (Cys561 in mouse sequence), the two
sites of S-nitrosylation observed in wild-type and eNOS-/- mice, revealed inhibition of glutamate
transport through reversible S-nitrosylation. The selective, nNOS-dependent S-nitrosylation of
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proteins that govern glutamate transport and metabolism identifies a previously unknown function
for ˙NO in glutamatergic neurotransmission.
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CHAPTER 1
Background
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1.1 Introduction
Since its initial discovery and characterization in the 1980s, nitric oxide (˙NO)
has become widely accepted as a critical signaling molecule in biological
function. Indeed, the field of ˙NO biology owes much to the pioneering work of
Furchgott, Ignarro, Murad, Moncada, and Hibbs, among others who identified
roles for ˙NO in vasodilation and immune responses to bacterial infection. The
significance of this research was further emphasized by the 1998 Nobel Prize in
Medicine and Physiology, which recognized ˙NO as a vital signaling intermediate
in the cardiovascular system (though it was appreciated in other systems as
well). ˙NO was initially thought to achieve its effects by binding to the heme iron
of soluble guanylate cyclase (sGC), resulting in the increased conversion of
guanosine-5’-triphosphate (GTP) to cyclic guanosine monophosphate (cGMP).
The ensuing activation of downstream cGMP-dependent signaling cascades
ultimately lead to physiological changes, such as smooth muscle relaxation.
However, an alternative mechanism of ˙NO-based regulation was discovered in
the early 1990s, in which ˙NO could form stable adducts with protein cysteine
residues to produce S-nitrosocysteine. The generation of such protein Snitrosocysteines was also found to result in physiological changes, including
vasodilation and platelet inhibition1. Subsequent studies have reinforced the
importance of this posttranslational modification (known as S-nitrosylation) as an
effector of ˙NO-dependent signaling2.
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Since that initial study in 1992, over 1100 S-nitrosocysteine residues have
been identified in more than 640 proteins across several cell and organ systems36.

These proteins are involved in a wide array of cellular processes, with S-

nitrosylation implicated as a direct regulator of protein function and subcellular
localization in multiple targets7-9. In particular, its physiological and
pathophysiological contributions to central nervous system (CNS) function have
elicited intense interest. Several studies have investigated the regulatory roles of
S-nitrosylation on specific proteins involved in neurogenesis10, synaptic
transmission11, and neurodegeneration12. However, such rigid focus on specific
targets has led to broader questions concerning the global coordination of
cellular processes by S-nitrosylation in the brain, especially under physiological
conditions. By employing an array of methodologies, ranging from mass
spectrometry (MS)-based proteomic identification of S-nitrosoproteins to more
conventional molecular biology and enzymatic approaches, one can start to
answer at least some of these questions. In doing so, a greater understanding of
˙NO’s role in both CNS development and dysfunction can be achieved, while also
providing valuable preliminary information for future studies.

1.2 Chemical Properties of Nitric Oxide
Nitric oxide (also known as nitrogen monoxide) is a gas that was first
described in 1774 by Joseph Priestly in his Experiments and Observations on
Different Kinds of Air, Vol. 1. A diatomic free radical, ˙NO consists of one
nitrogen and one oxygen atom, with an unpaired valence electron. Due to both
3

its low solubility in water13 (1.9 mM at 20°C) and liposome/water partition
coefficient14 of 4.4, ˙NO can diffuse readily through hydrophobic environments
(including the plasma membrane). Additionally, it can react with several targets
to generate a variety of end products15.
The reactive nature of ˙NO contributes to variations in its half-life, particularly
through its interactions with oxygen species. In aqueous solution, ˙NO reacts
with O2 and possesses a half-life inversely proportional to its concentration16-17.
In plasma and other physiological buffers, ˙NO oxidation to both nitrite (NO2-) and
nitrate (NO3-) is facilitated by hemoglobin and other proteins through heme and/or
other metal chemistries. The resulting ˙NO metabolites possess an extended
half-life18-19. Furthermore, nitric oxide can react with the free radical superoxide
(O2-) to produce the oxidant peroxynitrite (ONOO-), a reaction that is essentially
diffusion-rate limited20.
Metals and lipid-derived radicals can also act as targets of nitric oxide. Metal
nitrosyl (M-NO) complexes are readily formed through the coordination of nitric
oxide to transition metals such as iron and copper21-23, and are important in the
regulation of a number of enzymes24-25. Lipid peroxidation is also inhibited by the
interaction of ˙NO with lipid peroxyl radicals, which can occur at a rate near the
diffusion limit26-28.
Taken together, evidence suggests that the biological availability of ˙NO
(especially as a signaling molecule) is highly dependent on its local environment.
4

Given this information, it is necessary to understand three principles about nitric
oxide in vivo: how, when, and where it is produced. Fortunately, these questions
were answered by a number of landmark studies performed between the 1980s
and 1990s.

1.3 Biosynthesis of Nitric Oxide
The endogenous synthesis of ˙NO was first proposed in a study from 1916,
which noted a higher nitrate and nitrite concentration in human urine than could
be accounted for by dietary intake alone29. This finding was further confirmed by
isotopic balance experiments utilizing 15NO3-, which revealed that endogenous
production of nitrate (in this case, without 15N) was the source of excess nitrate in
urine30. However, the source of these metabolites remained elusive until 1987,
when the precursor to both nitrate and nitrate was demonstrated to be Larginine31-32. Specifically, 15N-labeling studies found that the nitrogen in both
NO2- and NO3- was derived from one of the two guanidino nitrogens in L-arginine,
while 14C-labeling studies identified L-citrulline as the other product32. This
mechanism was further characterized in later reports, with converging lines of
evidence suggesting ˙NO as an intermediate in the formation of nitrate and
nitrate33-34.
Nitric oxide is generated from L-arginine and oxygen, with L-citrulline
produced as a by-product. The reaction is catalyzed by three isoforms of the
enzyme nitric oxide synthase (NOS): NOS1 (neuronal NOS: nNOS), NOS2
5

(inducible NOS: iNOS), and NOS3 (endothelial NOS: eNOS). Of the three
isoforms, nNOS was the first to be purified and cloned35-36, with iNOS37 and
eNOS38-40 following soon afterwards. Each isoform is a homodimer assembly of
two 110-150 kDa monomers, composed of an N-terminal oxygenase domain and
a C-terminal reductase domain linked by a calmodulin recognition site41-42. The
oxygenase domain includes binding sites for the cofactors tetrahydrobiopterin
(BH4) and iron protoporphyrin IX, as well as a binding site for the substrate Larginine. The reductase domain contains binding sites for electron carriers flavin
mononucleotide (FMN) and flavin adenine dinucleotide (FAD), as well as a site
for the electron donor NADPH (the reduced form of nicotinamide adenine
dinucleotide phosphate). Electrons supplied by NADPH are transported across
the reductase domain by FAD and FMN to the heme group of iron protoporphyrin
IX in the oxygenase domain, where they can oxidize L-arginine. One of the
guanidino nitrogens in L-arginine undergoes a 5-electron oxidation through two
mono-oxygenation steps: the first producing Nω-hydroxyarginine (NOHA), which
is then oxidized to produce L-citrulline and ˙NO43-44. Calmodulin binding at its
cognate recognition site is thought to stabilize electron transfer between the
reductase FMN and the oxygenase heme45.
All three NOS isoforms are expressed in the brain, and catalyze the
production of ˙NO from L-arginine and oxygen. However, they differ in several
key respects, including functional regulation and levels of ˙NO production. Both
nNOS and eNOS are constitutively-expressed NOS isoforms and rely on calcium
6

(Ca2+) to initiate transient bursts of ˙NO synthesis: elevation of intracellular Ca2+
stimulates increased binding of calmodulin to both NOS isoforms, leading to the
generation of ˙NO46-48. The function of both isoforms is also subject to regulation
by multiple posttranslational modifications (PTMs), including palmitoylation,
phosphorylation, S-glutathionylation, and S-nitrosylation49-52. In contrast, iNOS
activity is less sensitive to changes in intracellular Ca2+, since the enzyme is far
more tightly bound to calmodulin to than either nNOS or eNOS37, 53. Expression
of this isoform is induced by inflammatory stimuli and results in prolonged periods
of ˙NO synthesis54-55. Much less is known regarding its functionally relevant
PTMs, though it has been found to be S-nitrosylated56. Of the three isoforms,
iNOS is thought to generate the highest amounts of ˙NO, with both nNOS and
eNOS producing orders of magnitude less57-58.
In addition to the dissimilarities already outlined, the NOS isoforms also differ
in sequence conservation and localization in the brain. Analysis of primary
amino acid sequences for the human NOS enzymes revealed only 51-60%
homology between the isoforms59. However, greater sequence homology for
specific isoforms was conserved between multiple species (>80% for iNOS
between mouse, rat, dog, and human), suggesting that ˙NO synthesis may be of
importance in mammalian evolution60. Given the functional and structural
diversity of the NOS isoforms, it is interesting to note their restricted expression
patterns in distinct cell types in the brain. nNOS is primarily expressed in defined
populations of neurons in the CNS, and associates with specific postsynaptic
7

complexes due to its PDZ domain61-62. iNOS, on the other hand, is mainly
expressed in the cytoplasm of astrocytes and microglia during inflammation63-64.
Finally, eNOS is chiefly expressed in the cytoplasm of both astrocytes and
vascular endothelial cells in the brain65-67.

1.4 Nitric Oxide in Physiology
1.4.1 Identification of Endothelial Nitric Oxide Synthesis
The long journey in characterizing endogenous biological synthesis of ˙NO
began in the latter half of the 17th century, with the discoveries of amyl nitrite and
nitroglycerin as potent vasodilators68-70. Despite these early studies, the actual
mechanism of action for these molecules (through the release of ˙NO or ˙NO
equivalent molecules) remained unknown for close to a century. In 1977, Ferid
Murad and colleagues realized that nitrite-containing compounds (including
nitroglycerin) and ˙NO gas had similar effects in stimulating sGC activity and
subsequent vascular dilation71, a finding reaffirmed in 1979 by Louis Ignarro’s
group72. Robert Furchgott and John Zawadzki made a parallel observation on
vasodilation in 1980, demonstrating that endothelial cells contributed toward the
relaxation of smooth muscle73. By 1982, Furchgott’s team speculated that this
action was achieved through release of an unstable relaxing substance, referred
to as endothelial relaxing factor74 (EDRF). Four years later, both Furchgott and
Ignarro presented independent findings at a vasodilation symposium suggesting
that EDRF was actually ˙NO. In the following year, this hypothesis was
confirmed by additional findings from Salvador Moncada’s group, who found that
8

endothelium-produced ˙NO derived from L-arginine accounted for EDRF’s
effects75-76. Ultimately, the source of endothelial ˙NO was shown to be eNOS3840.

Recognition of ˙NO’s importance in vasodilation came in 1998, with the

awarding of the 1998 Nobel Prize in Medicine and Physiology to Furchgott,
Ignarro, and Murad.
In the twenty years since those initial studies, multiple biological
processes have been found to be regulated by eNOS-derived ˙NO. Mice with a
genetic deletion of eNOS (eNOS-/-) exhibit hypertension, hypercoagulability, and
increased proliferation of vascular smooth muscle cells after vessel injury77-79.
Additionally, they demonstrate greater leukocyte/endothelium interaction,
increased infarct size after middle cerebral artery occlusion (MCAO), and
decreased beta-oxidation of fatty acids through very long chain acyl-CoA
dehydrogenase8, 80-81. Modulation of eNOS activity through phosphorylation at
serine 1176 has been shown to affect insulin sensitivity, regulation of insulin
levels, adiposity, and vascular reactivity82-83. Considered as a whole, the data
implicates eNOS-derived ˙NO in the global coordination of vascular and
metabolic function.
1.4.2 Nitric Oxide Synthesis and the Immune Response
Prior to Moncada’s findings, John Hibbs and colleagues identified Larginine as an essential substrate for nitrite synthesis following macrophage
activation31. In doing so, they provided one of the first examples for endogenous
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biosynthesis of nitric oxide (though this was not recognized until later).
Metabolism of L-arginine by macrophages was necessary for their cytotoxic
activity against target tumor cells84. However, the generation of ˙NO as an
intermediate in this process was not established until a series of studies
published between 1988 and 198933, 85-86. Consequently, the involvement of ˙NO
in several inflammatory cascades has been described87-90. Nitric oxide has been
shown to decrease cellular respiration through disruption of iron-sulfur clusters in
the electron transport chain91. Moreover, it can affect membrane potential
maintenance, DNA repair, lipid peroxidation, and other critical functions in target
cells92-94.
Eventually, the chief source of ˙NO in macrophages and other immune
cells was found to be iNOS37, which is upregulated in response to inflammatory
cytokines and other stimuli. Mice with a genetic deletion of iNOS (iNOS-/-) are
phenotypically similar to wild-type (WT) mice under normal conditions. However,
they are more susceptible to parasitic infection, bacterial proliferation, and
intestinal tumorigenesis95-98. Concomitantly, they are resistant to sepsis-induced
hypotension, inflammation-induced osteoporosis, and ischemia-induced
neurodegeneration in the brain96, 99-101. Taken together, the evidence suggests
iNOS-derived ˙NO as a local inducible regulator of the immune response to
pathogens and cellular damage.
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1.4.3 Nitric Oxide and the Central Nervous System
Given its systemic nature as a signaling molecule, it is no surprise that
nitric oxide also influences brain physiology. Early studies in the cerebellum
implicated ˙NO synthesis as an intermediate step between N-methyl-D-aspartate
(NMDA) receptor stimulation by glutamate and cGMP synthesis102-103. In doing
so, they provided a first glimpse into nitric oxide’s role in neurotransmitter signal
transduction. These findings were later followed up by multiple observations of
˙NO’s contribution to long-term potentiation (LTP), a measure of synaptic
plasticity104-108.
Subsequent investigations have identified nitric oxide as a critical
participant in several biological processes in the CNS. Presynaptic vesicular
release and recycling is potentiated by nitric oxide through increased SNARE
complex assembly and regulation of phosphatidylinositol 4, 5-biphosphate
(PIP2)-dependent processes109-111. Exoendocytic coupling and glutamate/GABA
release during neurotransmission is facilitated by ˙NO-based activation of
presynaptic hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
and protein kinase G112-116 (PKG). Similarly, presynaptic remodeling is
accomplished through ˙NO-dependent kainate receptor recruitment and activitydependent synaptogenesis117-119. On the postsynaptic side, ˙NO has been
shown to modulate target neuron excitability through regulation of Kv2/Kv3
potassium channel activity and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptor trafficking120-122. Finally, ˙NO-dependent upregulation of
11

glycolysis in astrocytes has been shown to be important in supporting changes in
neuronal activity123-124.
Much of the work documenting ˙NO’s effects on the CNS was only made
possible by the initial purification and characterization of nNOS, the first NOS
isoform to be isolated35-36. In particular, discovery of postsynaptic tethering
between the NMDA receptor, PSD-95, and nNOS provided a molecular
explanation for the association between synaptic transmission and ˙NO
production/activity62, 125. Upon presynaptic release of glutamate into the synaptic
cleft, it is free to bind to the postsynaptic NMDA receptor (along with a receptor
co-agonist, either glycine or D-serine). Once activated, the NMDA receptor
allows Ca2+ to enter the neuron. Due to the close proximity of the NMDA
receptor to nNOS afforded by the PSD-95 scaffold, this Ca2+ influx subsequently
leads to ˙NO synthesis.
Predictably, loss of nNOS has profound effects on CNS function. Mice
with a genetic deletion of this isoform (nNOS-/-) demonstrate substantially
decreased NO production (>90%) relative to WT mice126. Consequently, they
exhibit a number of phenotypic deficits, including impairments in various forms of
recognition, fear conditioning, working memory, and other cognitive functions127130.

Many, if not all, of these insufficiencies may be symptomatic of widespread

synaptic dysfunction across the brain: several reports have documented
decreases in both synaptic potentiation and depression in these mice relative to
WT animals131-132. Correspondingly, nNOS-/- mice also demonstrate an
12

attenuated cerebral blood flow response to increased synaptic activity,
suggesting a local influence for nNOS-derived ˙NO beyond the specific
coordination of presynaptic and postsynaptic neurons133.
In addition to the physiological effects of nNOS-derived ˙NO observed in
the CNS, a number of pathophysiological effects have also been identified in
recent years. Most prominently, dysfunctional ˙NO production by nNOS is
heavily implicated in the pathological progression of cerebral ischemia.
Disruption of PSD-95/nNOS coupling has been shown to be neuroprotective after
MCAO in rodents, a finding consistent with the reduced cell death seen in nNOS/-

mice after MCAO134-135. Similarly, in an MPP+ model of dopaminergic

neurodegeneration, genetic deletion or pharmacological inhibition of nNOS
proved effective in preserving neuronal viability136-137. Indeed, excessive nNOS
activity is implicated in the abnormal regulation of a number of different proteins
that contribute to neurodegeneration, including peroxiredoxin-2138 (Prx2), Xlinked inhibitor of apoptosis12 (XIAP), glyceraldehyde-3-phosphate
dehydrogenase7 (GAPDH), and parkin139. Much of this disproportionate
synthesis of ˙NO may be due to the high levels of extracellular glutamate present
after initial cellular degeneration the CNS: the resultant stimulation of surrounding
neuronal NMDA receptors could activate nNOS into producing
supraphysiological levels of ˙NO in response140. Considered as a whole, the
evidence indicates that the difference between physiological and
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pathophysiological function in the CNS may be regulated, at least in part, through
nNOS-derived ˙NO.

1.5 Mechanisms of Nitric Oxide-Based Signaling
1.5.1 Activation of sGC/cGMP Cascades
Soluble guanylate cyclase (sGC) is one of two main subtypes of the
guanylyl cyclase enzyme, which is responsible for catalyzing the production of
cGMP and pyrophosphate from GTP. Three subunits of the enzyme have been
identified: α1, α2, and β1. A functional complex of the enzyme consists of a
heterodimer of α and β subunits, resulting in two isoforms of sGC: α1β1 and α2β1.
Both isoforms are expressed in the brain, and exhibit regional differences in
expression: α1β1 is more prominent in the caudate/putamen and nucleus
accumbens, while α2β1 is expressed at higher levels in the hippocampus and
olfactory bulb141-142.
Nitric oxide acts on sGC through direct binding to the N-terminal hemecontaining domain of the enzyme’s β1 subunit. The heme group of sGC shows
exquisite sensitivity for ˙NO over O2, with the ability to detect ˙NO in the presence
of a 10,000-fold excess of O2 and an EC50 for ˙NO between 1-2 nM143-144. One of
the current models postulates that binding of ˙NO to the heme group leads to the
release of an Fe2+-ligated histidine residue from the heme group, leading to
conformational changes in the enzyme that are transduced to the catalytic
domain. Subsequently, this allows for the binding of other ˙NO molecules to
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lower-affinity sites on the protein, and results in significantly upregulated cGMP
production145. Presynaptically, ˙NO synthesis and subsequent sGC activity is
primarily initiated by action potential-dependent Ca2+ flux through N-type
channels146. Postsynaptic sGC activity is chiefly dependent on NMDA receptormediated Ca2+ flux, due to its association through PSD-95 to both the NMDA
receptor and nNOS147.
˙NO-dependent changes in cGMP production are vital in mediating
downstream biological processes in the CNS. For example, they can regulate
Na+, Ca2+, and K+ flux though CNG and HCN channels, thereby modulating
neuronal excitability147-148. Additionally, they can lead to autoregulation of cyclic
nucleotide levels through the activation of specific phosphodiesterases (including
PDE2, PDE5, and PDE6), leading to reductions in cAMP/cGMP signaling149.
Alternatively, ˙NO can exert its effects on cGMP signaling cascades through the
regulation of cGMP-dependent protein kinase (PKG) activity. This process has
been implicated in a variety of different functions in the CNS, including vesicular
GABA release112, K+ flux through Kv1.1/1.2 channels150, ryanodine receptor
(RyR)-dependent Ca2+ release from internal stores151, and other pathways152.
Despite the evidence supporting cGMP signaling as a relevant ˙NO
effector, it was soon recognized that it was not the only pathway available for
˙NO-dependent regulation of biological function. Inhibition of cGMP synthesis did
not completely block many of the ˙NO-dependent effects observed in brain
physiology, indicating a yet-undiscovered regulatory avenue by ˙NO that
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extended beyond phosphorylation-dependent signaling cascades153-156.
Eventually, this led to the identification of S-nitrosylation as another mechanism
through which ˙NO could influence protein structure and function.
1.5.2 Protein S-Nitrosylation
S-nitrosothiols were first identified by Tasker and Jones in 1909, after
treatment of ethane-thiol with nitrosyl chloride157. The biological utility of this
chemical species was not noted until a series of studies by Ignarro and
colleagues in the 1980s, which demonstrated novel properties for S-nitrosothiols
in smooth muscle relaxation and anti-platelet aggregation158-159. These effects
were initially attributed to the activation of sGC by ˙NO released from the thiol.
However, by 1990 Kowaluk and Fung concluded that a number of the bioactive
effects of S-nitrosothiols could not be solely accounted for by decomposition to
˙NO160. These findings were soon extended by Stamler and colleagues in 1992,
who found that protein thiols could undergo the transformation to S-nitrosothiols
under physiological conditions and thereby extend the half-life of ˙NO: the
resultant S-nitrosoproteins also possessed vasodilatory and platelet aggregation
effects1, similar to EDRF/˙NO. Subsequent identification of endogenous Snitrosoalbumin in blood plasma confirmed the in vivo biosynthesis of Snitrosoproteins, and opened up a new field of ˙NO biology for further study161.
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1.5.2.1 Mechanisms of Protein S-Nitrosylation and De-Nitrosylation
Several biochemical mechanisms of protein S-nitrosocysteine formation (ProtSNO) have been proposed, both nonenzymatic and enzymatic. The first involves
the autooxidation of ˙NO through its reaction with O2, resulting in the generation
of a series of nitrogen oxides162.
1) ˙NO + O2

ONOO

2) ONOO + ˙NO
3) N2O4

N2O4

2˙NO2

4) ˙NO2 + ˙NO

N2O3

5) N2O3 + Prot-SH

Prot-SNO + H+ + NO2-

N2O3 is considered a potent nitrosating agent, and is thought to react with protein
thiols (Prot-SH) to generate protein S-nitrosocysteine. The rate constant for
N2O3 formation in aqueous environments (2-5 x 106 M-2 s-1) is thought to render it
impractical under physiological conditions, due to the rate-limiting formation of
NO217, 163-166. Despite this limitation, it may be favored in localized cellular
compartments, due to a few key factors. The reaction rate for N2O3 generation is
very sensitive to reactant concentration, especially that of ˙NO. Additionally, the
rate constant for the reaction can increase up to 300-fold in hydrophobic
environments such as biological membranes167-169. Given the lipophilic nature of
˙NO, both of these requirements may be met at sufficient enough levels in
compartmentalized membrane environments to generate local nitrosating
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species170. Alternatively, another mechanism for S-nitrosylation relies on the
generation of protein thiyl radical (Prot-S˙) from the reaction between NO2 and a
cysteine thiol171.
1) NO2 + Prot-SH
2) ˙NO + Prot-S˙

Prot-S˙ + H+ + NO2Prot-SNO

However, this process still relies on the rate-limiting formation of NO2, leaving it
with the same restrictions as N2O3.
A second demonstrated mechanism for protein S-nitrosylation depends on
the direct reaction of ˙NO with a transition metal (Me(n+1)+), such as Fe3+ or Cu2+.
This results in the reduction of the metal, as well as the generation of a
nitrosonium (NO+) ion, at rates more physiologically relevant than those observed
for NO2/N2O3 formation. The nitrosonium, subsequently, is free to react with
local cysteine thiols172-174.
1) Me(n+1)+ + ˙NO

Me(n)-NO+

2) Me(n)+-NO+ + Prot-SH

Prot-SNO + Me(n)+ + H+

Another related mechanism for protein S-nitrosylation relies on the generation of
dinitrosyl-iron complexes from ˙NO and free iron pools, which can then lead to
subsequent protein S-nitrosylation175-177.
A third mechanism of protein S-nitrosylation involves the reversible
transfer of a nitrosonium group between cysteine thiols, referred to as trans-
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nitrosylation. The source of the nitrosonium can be either a low molecular weight
S-nitrosothiol, such as S-nitrosoglutathione (GSNO), or another protein Snitrosocysteine (the second scenario is referred to as protein-assisted transnitrosylation: this includes protein de-nitrosylation as well).
1) Prot-SH + GSNO ↔ GSH + Prot-SNO
2) Prot1-SNO + Prot2-SH ↔ Prot1-SH + Prot2-SNO

Intracellular pools of glutathione (GSH) and GSNO are major endogenous
sources of nitrosonium acceptors and donors, respectively161, 178-181. Together
with existing protein thiols and S-nitrosothiols, they provide the substrates
necessary for the regulation of cellular processes.
The biosynthetic mechanisms underlying intracellular GSNO formation under
aerobic conditions remain unclear, although it may require either ˙NO
autooxidation to N2O3 or the reaction of ˙NO with a glutathionyl radical (GS˙).
Alternatively, it may be generated through the generation of a thionitroxide
intermediate182 (GSNO-H), which can then reduce molecular oxygen and result in
superoxide (O2-) and GSNO.
1) GSH + ˙NO
2) GSNO-H + O2

GSNO-H
GSNO + O2-

GSNO levels are maintained by several different enzymes, such as Snitrosoglutathione reductase (GSNO-R), carbonyl reductase 1 (CR1), thioredoxin
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(Trx), and γ-glutamyl transpeptidase (γ-GT). In doing so, they may indirectly
influence protein S-nitrosylation in a number of different tissues through the
regulation of available nitrosonium from GSNO183-186.
Protein-assisted trans-nitrosylation represents an additional avenue of
˙NO-dependent signal transduction, though one that remains relatively
unexplored. One of the first trans-nitrosylation-dependent “cascades” described
involves the regulation of caspase-dependent cell death by thioredoxin.
Thioredoxin modulates the Fas-induced activation of caspase-3 through transnitrosylation/de-nitrosylation of caspase-3, with caspase de-nitrosylation a
prerequisite for apoptosis185, 187. Similarly, GAPDH-mediated trans-nitrosylation
of Siah has been identified as a key contributor to neuronal apoptosis7, 188. A
third recently elucidated pathway involves the assembly of proteins in the
interferon-gamma (IFN-γ)-activated inhibitor of translation (GAIT) complex, a
process dependent on S100A9-mediated trans-nitrosylation189. Additional
studies have identified candidate de-nitrosylases in the regulation of cellular Snitrosothiol levels, including protein disulfide isomerase, xanthine oxidase,
superoxide dismutase, and glutathione peroxidase190-193. Given the large
number of S-nitrosoproteins already identified, these pathways may only
represent a small fraction of the trans-nitrosylation-dependent processes
involved in physiological function.
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1.5.2.2 Selectivity of S-Nitrosylation
Although significant progress has been made in identifying the protein
substrates of S-nitrosylation, the selectivity behind the endogenous modification
of specific cysteine residues is not as well-described. Several attempts have
been made to decipher the biophysical and biochemical requirements behind in
vivo S-nitrosylation of cysteine residues with mixed results. Analysis of protein
S-nitrosocysteines identified in the WT mouse liver found them to be
overrepresented in α-helical structures, with locations in larger surfaceaccessible areas and proximal (within a 6-A radius) to charged amino acids194.
However, these structural characteristics could not account for all Snitrosocysteines identified, a finding confirmed in a later survey of Snitrosocysteines identified in multiple mouse organs4-5. Additional studies have
indicated that charged residues distal to specific cysteine residues could
participate in protein-protein interactions that may facilitate S-nitrosylation of
those cysteine residues, with proximal acid/base motifs thought to play a role in
this process as well195-196. S-nitrosocysteines have also been found near metal
centers of proteins176, 197-198, a fact that may be important given the known ability
of certain transition metals to coordinate to ˙NO. Recently, a I/L-X-C-X2-D/E
motif for protein trans-nitrosylation has been discovered in members of the GAIT
complex189, which become S-nitrosylated by iNOS-derived ˙NO in response to
IFN-γ and oxidized low-density lipoprotein (LDLOX). When considered as a
whole, the evidence suggests that multiple mechanisms may be involved in the
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selectivity of S-nitrosocysteine formation in proteins. This, in turn, would result in
the diverse subset of S-nitrosoproteins detected thus far.
1.5.2.3 S-Nitrosylation and Protein Function in the CNS
As an alternative pathway for ˙NO-dependent cell signaling, S-nitrosylation
has garnered intense interest in the CNS. A survey of prior reports has yielded
more than 170 proteins with 323 S-nitrosocysteine residues in vivo in rodent
brain. Of these proteins and sites, only 120 proteins with 181 sites were found
under physiological conditions, suggesting a biased association in the literature
between S-nitrosylation and cell death in the brain. On the other hand, additional
roles have also been observed for protein S-nitrosylation in neuronal
development and synaptic transmission. Collectively, the existing information
suggests a functional pleiotropy for this modification during both normal
physiology and disease in the CNS, similar to phosphorylation or acetylation199200.

Several groups have focused on the contributions of S-nitrosylation of
specific protein targets to neurodegeneration. These include, among others, the
inhibition of parkin E3 ubiquitin ligase activity139, GAPDH-induced apoptosis7, 201,
caspase activation via XIAP inhibition12, PTEN-dependent regulation of PI3/Akt
signaling202, and MEF2-mediated transcriptional regulation10. The widespread
effects of S-nitrosylation in multiple processes, ranging from transcriptional
repression of specific genes to perturbations in numerous cell survival pathways,
imply a large contribution from ˙NO to the pathological effects observed in many
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chronic neurological disorders (such as Alzheimer’s or Parkinson’s disease).
Despite such findings, however, it is the effects of endogenous S-nitrosylation on
physiological function that are gaining recognition for their importance in refining
and maintaining critical biological processes within the brain.
In recent years, the significance of this modification in normal CNS
development has become increasingly apparent. S-nitrosylation of transcription
factor MEF2A prevents it from binding to specific promoters, leading to
decreased expression of the nuclear receptor tailless and subsequent
impairments in neurogenesis and neuronal differentiation10. Transduction of the
BDNF/CREB-dependent signaling cascade is achieved through the Snitrosylation of effector molecules, including sirtuin-1 (SIRT1) and histone
deacetylase 2 (HDAC2), resulting in gene expression changes that affect
neuronal differentiation and axodendritic morphology201, 203-204. Furthermore,
axonal retraction is partly guided via S-nitrosylation of the light chain of
microtubule-associated protein 1B (MAP1B), thereby affecting growth cone
dynamics during CNS maturation205. Given this evidence, a case can be made
for protein S-nitrosylation as a “synaptic tag”, linking neuronal signaling (via
glutamate and postsynaptic ˙NO production by nNOS) to longstanding changes
in synaptic plasticity206.
Perhaps most interesting are the documented effects of S-nitrosylation on
protein function at the synapse itself. It regulates cation flux through NMDA207
and AMPA208 receptors, as well as the attachment of scaffold protein PSD-95 to
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the postsynaptic plasma membrane11. Additionally, it governs postsynaptic
AMPA receptor trafficking209-210 and gephyrin clustering211 in response to
glutamatergic and GABAergic activity, respectively. Finally, D-serine production
is decreased by S-nitrosylation of serine racemase212, leading to its reduced
availability as a coagonist for synaptic NMDA receptor activation213. Taken
together, these data suggest S-nitrosylation as a potent coordinator of both shortterm and long-term responses to synaptic transmission. However, since
previous reports of the modification in the CNS primarily focused on analyses of
single proteins, investigation of this hypothesis may be better aided by largescale in vivo proteomic identification of endogenously S-nitrosylated proteins
from the brain. Most of the approaches developed thus far for such studies are
outlined in the next chapter. Moreover, it leads to the central questions of our
study in Chapter 3, namely:
1) Which targets of S-nitrosylation in the brain are involved in the regulation
of synaptic function?
2) What is the source of ˙NO utilized for the modification of these proteins
(this may also contribute to spatial localization/modification of these
proteins)?
3) What are the functional effects of this modification in these proteins, and
how do they contribute to neurotransmission as a whole?

24

References
[1]

J.S. Stamler, D.I. Simon, J.A. Osborne, M.E. Mullins, O. Jaraki, T. Michel, D.J. Singel, J.
Loscalzo. S-nitrosylation of proteins with nitric oxide: Synthesis and characterization of
biologically active compounds Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 444-448.

[2]

M.W. Foster, D.T. Hess, J.S. Stamler. Protein S-nitrosylation in health and disease: A
current perspective Trends Mol. Med. 15 (2009) 391-404.

[3]

D. Seth, J.S. Stamler. The SNO-proteome: Causation and classifications Curr. Opin. Chem.
Biol. 15 (2011) 129-136.

[4]

N. Gould, P.T. Doulias, M. Tenopoulou, K. Raju, H. Ischiropoulos. Regulation of protein
function and signaling by reversible cysteine S-nitrosylation J. Biol. Chem. 288 (2013)
26473-26479.

[5]

P.T. Doulias, M. Tenopoulou, K. Raju, L.A. Spruce, S.H. Seeholzer, H. Ischiropoulos. Site
specific identification of endogenous S-nitrosocysteine proteomes J. Proteomics 92 (2013)
195-203.

[6]

M. Zareba-Koziol, A. Szwajda, M. Dadlez, A. Wyslouch-Cieszynska, M. Lalowski. Global
analysis of S-nitrosylation sites in the wild type (APP) transgenic mouse brain-clues for
synaptic pathology Mol. Cell. Proteomics 13 (2014) 2288-2305.

[7]

M.R. Hara, N. Agrawal, S.F. Kim, M.B. Cascio, M. Fujimuro, Y. Ozeki, M. Takahashi, J.H.
Cheah, S.K. Tankou, L.D. Hester, C.D. Ferris, S.D. Hayward, S.H. Snyder, A. Sawa. Snitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1
binding Nat. Cell Biol. 7 (2005) 665-674.

[8]

P.T. Doulias, M. Tenopoulou, J.L. Greene, K. Raju, H. Ischiropoulos. Nitric oxide regulates
mitochondrial fatty acid metabolism through reversible protein S-nitrosylation Sci. Signal. 6
(2013) rs1.

[9]

Y.I. Lee, D. Giovinazzo, H.C. Kang, Y. Lee, J.S. Jeong, P.T. Doulias, Z. Xie, J. Hu, M.
Ghasemi, H. Ischiropoulos, J. Qian, H. Zhu, S. Blackshaw, V.L. Dawson, T.M. Dawson.
Protein microarray characterization of the S-nitrosoproteome Mol. Cell. Proteomics 13
(2014) 63-72.

[10] S. Okamoto, T. Nakamura, P. Cieplak, S.F. Chan, E. Kalashnikova, L. Liao, S. Saleem, X.
Han, A. Clemente, A. Nutter, S. Sances, C. Brechtel, D. Haus, F. Haun, S. Sanz-Blasco,
X. Huang, H. Li, J.D. Zaremba, J. Cui, Z. Gu, R. Nikzad, A. Harrop, S.R. McKercher, A.
Godzik, J.R. Yates 3rd, S.A. Lipton. S-nitrosylation-mediated redox transcriptional switch
modulates neurogenesis and neuronal cell death Cell. Rep. 8 (2014) 217-228.
[11] G.P. Ho, B. Selvakumar, J. Mukai, L.D. Hester, Y. Wang, J.A. Gogos, S.H. Snyder. Snitrosylation and S-palmitoylation reciprocally regulate synaptic targeting of PSD-95 Neuron
71 (2011) 131-141.
[12] A.H. Tsang, Y.I. Lee, H.S. Ko, J.M. Savitt, O. Pletnikova, J.C. Troncoso, V.L. Dawson, T.M.
Dawson, K.K. Chung. S-nitrosylation of XIAP compromises neuronal survival in parkinson's
disease Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 4900-4905.

25

[13] A.W. Shaw, A.J. Vosper. Solubility of nitric oxide in aqueous and nonaqueous solvents
Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed
Phases 73 (1977) 1239.
[14] M. Moller, H. Botti, C. Batthyany, H. Rubbo, R. Radi, A. Denicola. Direct measurement of
nitric oxide and oxygen partitioning into liposomes and low density lipoprotein J. Biol. Chem.
280 (2005) 8850-8854.
[15] J.S. Beckman, W.H. Koppenol. Nitric oxide, superoxide, and peroxynitrite: The good, the
bad, and ugly Am. J. Physiol. 271 (1996) C1424-37.
[16] L.J. Ignarro, J.M. Fukuto, J.M. Griscavage, N.E. Rogers, R.E. Byrns. Oxidation of nitric oxide
in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric
oxide from L-arginine Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 8103-8107.
[17] D.A. Wink, J.F. Darbyshire, R.W. Nims, J.E. Saavedra, P.C. Ford. Reactions of the
bioregulatory agent nitric oxide in oxygenated aqueous media: Determination of the kinetics
for oxidation and nitrosation by intermediates generated in the NO/O2 reaction Chem. Res.
Toxicol. 6 (1993) 23-27.
[18] K. Yoshida, K. Kasama, M. Kitabatake, M. Imai. Biotransformation of nitric oxide, nitrite and
nitrate Int. Arch. Occup. Environ. Health 52 (1983) 103-115.
[19] M. Kelm. Nitric oxide metabolism and breakdown Biochim. Biophys. Acta 1411 (1999) 273289.
[20] J.S. Beckman, T.W. Beckman, J. Chen, P.A. Marshall, B.A. Freeman. Apparent hydroxyl
radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and
superoxide Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 1620-1624.
[21] J.H. Enemark, R.D. Feltham. Principles of structure, bonding, and reactivity for metal nitrosyl
complexes Coord. Chem. Rev. 13 (1974) 339-406.
[22] D.A. Wink, C.B. Wink, R.W. Nims, P.C. Ford. Oxidizing intermediates generated in the
fenton reagent: Kinetic arguments against the intermediacy of the hydroxyl radical Environ.
Health Perspect. 102 Suppl 3 (1994) 11-15.
[23] J.A. McCleverty. Chemistry of nitric oxide relevant to biology Chem. Rev. 104 (2004) 403418.
[24] J.C. Drapier, J.B. Hibbs Jr. Aconitases: A class of metalloproteins highly sensitive to nitric
oxide synthesis Methods Enzymol. 269 (1996) 26-36.
[25] A. Hausladen, I. Fridovich. Measuring nitric oxide and superoxide: Rate constants for
aconitase reactivity Methods Enzymol. 269 (1996) 37-41.
[26] V.B. O'Donnell, P.H. Chumley, N. Hogg, A. Bloodsworth, V.M. Darley-Usmar, B.A. Freeman.
Nitric oxide inhibition of lipid peroxidation: Kinetics of reaction with lipid peroxyl radicals and
comparison with alpha-tocopherol Biochemistry 36 (1997) 15216-15223.

26

[27] N. Hogg, B. Kalyanaraman. Nitric oxide and lipid peroxidation Biochim. Biophys. Acta 1411
(1999) 378-384.
[28] H. Rubbo, R. Radi, D. Anselmi, M. Kirk, S. Barnes, J. Butler, J.P. Eiserich, B.A. Freeman.
Nitric oxide reaction with lipid peroxyl radicals spares alpha-tocopherol during lipid
peroxidation: greater oxidant protection from the pair nitric oxide/alpha-tocopherol than
alpha-tocopherol/ascorbate J. Biol. Chem. 275 (2000) 10812-10818.
[29] H.H. Mitchell, H. Shonle, H. Grindley. The origin of nitrate in the urine J Biol Chem 24 (1916)
461-490.
[30] L.C. Green, K. Ruiz de Luzuriaga, D.A. Wagner, W. Rand, N. Istfan, V.R. Young, S.R.
Tannenbaum. Nitrate biosynthesis in man Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 77647768.
[31] J.B. Hibbs Jr, R.R. Taintor, Z. Vavrin. Macrophage cytotoxicity: Role for L-arginine
deiminase and imino nitrogen oxidation to nitrite Science 235 (1987) 473-476.
[32] R. Iyengar, D.J. Stuehr, M.A. Marletta. Macrophage synthesis of nitrite, nitrate, and Nnitrosamines: Precursors and role of the respiratory burst Proc. Natl. Acad. Sci. U.S.A. 84
(1987) 6369-6373.
[33] M.A. Marletta, P.S. Yoon, R. Iyengar, C.D. Leaf, J.S. Wishnok. Macrophage oxidation of Larginine to nitrite and nitrate: Nitric oxide is an intermediate Biochemistry 27 (1988) 87068711.
[34] R.M. Palmer, D.D. Rees, D.S. Ashton, S. Moncada. L-arginine is the physiological precursor
for the formation of nitric oxide in endothelium-dependent relaxation Biochem. Biophys. Res.
Commun. 153 (1988) 1251-1256.
[35] D.S. Bredt, S.H. Snyder. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme
Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 682-685.
[36] D.S. Bredt, P.M. Hwang, C.E. Glatt, C. Lowenstein, R.R. Reed, S.H. Snyder. Cloned and
expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase Nature
351 (1991) 714-718.
[37] Q.W. Xie, H.J. Cho, J. Calaycay, R.A. Mumford, K.M. Swiderek, T.D. Lee, A. Ding, T. Troso,
C. Nathan. Cloning and characterization of inducible nitric oxide synthase from mouse
macrophages Science 256 (1992) 225-228.
[38] T. Michel, S. Lamas. Molecular cloning of constitutive endothelial nitric oxide synthase:
Evidence for a family of related genes J. Cardiovasc. Pharmacol. 20 Suppl 12 (1992) S45-9.
[39] S.P. Janssens, A. Shimouchi, T. Quertermous, D.B. Bloch, K.D. Bloch. Cloning and
expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide
synthase J. Biol. Chem. 267 (1992) 14519-14522.
[40] P.A. Marsden, K.T. Schappert, H.S. Chen, M. Flowers, C.L. Sundell, J.N. Wilcox, S. Lamas,
T. Michel. Molecular cloning and characterization of human endothelial nitric oxide synthase
FEBS Lett. 307 (1992) 287-293.

27

[41] D.K. Ghosh, D.J. Stuehr. Macrophage NO synthase: Characterization of isolated oxygenase
and reductase domains reveals a head-to-head subunit interaction Biochemistry 34 (1995)
801-807.
[42] B.R. Crane, A.S. Arvai, D.K. Ghosh, C. Wu, E.D. Getzoff, D.J. Stuehr, J.A. Tainer. Structure
of nitric oxide synthase oxygenase dimer with pterin and substrate Science 279 (1998)
2121-2126.
[43] N.S. Kwon, C.F. Nathan, C. Gilker, O.W. Griffith, D.E. Matthews, D.J. Stuehr. L-citrulline
production from L-arginine by macrophage nitric oxide synthase. the ureido oxygen derives
from dioxygen J. Biol. Chem. 265 (1990) 13442-13445.
[44] A.M. Leone, R.M. Palmer, R.G. Knowles, P.L. Francis, D.S. Ashton, S. Moncada.
Constitutive and inducible nitric oxide synthases incorporate molecular oxygen into both
nitric oxide and citrulline J. Biol. Chem. 266 (1991) 23790-23795.
[45] B.C. Smith, E.S. Underbakke, D.W. Kulp, W.R. Schief, M.A. Marletta. Nitric oxide synthase
domain interfaces regulate electron transfer and calmodulin activation Proc. Natl. Acad. Sci.
U.S.A. 110 (2013) E3577-86.
[46] P.F. Chen, K.K. Wu. Characterization of the roles of the 594-645 region in human
endothelial nitric-oxide synthase in regulating calmodulin binding and electron transfer J.
Biol. Chem. 275 (2000) 13155-13163.
[47] E.D. Garcin, C.M. Bruns, S.J. Lloyd, D.J. Hosfield, M. Tiso, R. Gachhui, D.J. Stuehr, J.A.
Tainer, E.D. Getzoff. Structural basis for isozyme-specific regulation of electron transfer in
nitric-oxide synthase J. Biol. Chem. 279 (2004) 37918-37927.
[48] D.E. Spratt, V. Taiakina, M. Palmer, J.G. Guillemette. Differential binding of calmodulin
domains to constitutive and inducible nitric oxide synthase enzymes Biochemistry 46 (2007)
8288-8300.
[49] L. Zhou, D.Y. Zhu. Neuronal nitric oxide synthase: Structure, subcellular localization,
regulation, and clinical implications Nitric Oxide 20 (2009) 223-230.
[50] R. Rafikov, F.V. Fonseca, S. Kumar, D. Pardo, C. Darragh, S. Elms, D. Fulton, S.M. Black.
eNOS activation and NO function: Structural motifs responsible for the posttranslational
control of endothelial nitric oxide synthase activity J. Endocrinol. 210 (2011) 271-284.
[51] C.A. Chen, T.Y. Wang, S. Varadharaj, L.A. Reyes, C. Hemann, M.A. Talukder, Y.R. Chen,
L.J. Druhan, J.L. Zweier. S-glutathionylation uncouples eNOS and regulates its cellular and
vascular function Nature 468 (2010) 1115-1118.
[52] Z. Altaany, Y. Ju, G. Yang, R. Wang. The coordination of S-sulfhydration, S-nitrosylation,
and phosphorylation of endothelial nitric oxide synthase by hydrogen sulfide Sci. Signal. 7
(2014) ra87.
[53] R.C. Venema, H.S. Sayegh, J.D. Kent, D.G. Harrison. Identification, characterization, and
comparison of the calmodulin-binding domains of the endothelial and inducible nitric oxide
synthases J. Biol. Chem. 271 (1996) 6435-6440.

28

[54] J. MacMicking, Q.W. Xie, C. Nathan. Nitric oxide and macrophage function Annu. Rev.
Immunol. 15 (1997) 323-350.
[55] G.C. Brown. Mechanisms of inflammatory neurodegeneration: INOS and NADPH oxidase
Biochem. Soc. Trans. 35 (2007) 1119-1121.
[56] R.J. Rosenfeld, J. Bonaventura, B.R. Szymczyna, M.J. MacCoss, A.S. Arvai, J.R. Yates 3rd,
J.A. Tainer, E.D. Getzoff. Nitric-oxide synthase forms N-NO-pterin and S-NO-cys:
Implications for activity, allostery, and regulation J. Biol. Chem. 285 (2010) 31581-31589.
[57] C. Nathan. Nitric oxide as a secretory product of mammalian cells Faseb J. 6 (1992) 30513064.
[58] P.L. Huang. eNOS, metabolic syndrome and cardiovascular disease Trends Endocrinol.
Metab. 20 (2009) 295-302.
[59] W.K. Alderton, C.E. Cooper, R.G. Knowles. Nitric oxide synthases: Structure, function and
inhibition Biochem. J. 357 (2001) 593-615.
[60] X. Wang, C.G. McGregor, V.M. Miller. Induction and cDNA sequence of inducible nitric oxide
synthase from canine aortic smooth muscle cells Am. J. Physiol. 275 (1998) H1122-9.
[61] D.S. Bredt, P.M. Hwang, S.H. Snyder. Localization of nitric oxide synthase indicating a
neural role for nitric oxide Nature 347 (1990) 768-770.
[62] J.E. Brenman, D.S. Chao, S.H. Gee, A.W. McGee, S.E. Craven, D.R. Santillano, Z. Wu, F.
Huang, H. Xia, M.F. Peters, S.C. Froehner, D.S. Bredt. Interaction of nitric oxide synthase
with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ
domains Cell 84 (1996) 757-767.
[63] E. Galea, D.L. Feinstein, D.J. Reis. Induction of calcium-independent nitric oxide synthase
activity in primary rat glial cultures Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10945-10949.
[64] M. Endoh, K. Maiese, J. Wagner. Expression of the inducible form of nitric oxide synthase by
reactive astrocytes after transient global ischemia Brain Res. 651 (1994) 92-100.
[65] M. Barna, T. Komatsu, C.S. Reiss. Activation of type III nitric oxide synthase in astrocytes
following a neurotropic viral infection Virology 223 (1996) 331-343.
[66] A. Stanarius, I. Topel, S. Schulz, H. Noack, G. Wolf. Immunocytochemistry of endothelial
nitric oxide synthase in the rat brain: A light and electron microscopical study using the
tyramide signal amplification technique Acta Histochem. 99 (1997) 411-429.
[67] K. Iwase, K. Miyanaka, A. Shimizu, A. Nagasaki, T. Gotoh, M. Mori, M. Takiguchi. Induction
of endothelial nitric-oxide synthase in rat brain astrocytes by systemic lipopolysaccharide
treatment J. Biol. Chem. 275 (2000) 11929-11933.
[68] T.L. Brunton. On the use of nitrite of amyl in angina pectons Lancet 2 (1867) 97-98.
[69] W. Murrell. Nitro-glycerine as a remedy for angina pectoris Lancet 1 (1879) 80-81, 113115, 151-152, 225-227.

29

[70] W.B. Fye. T. Lauder Brunton and amyl nitrite: A Victorian vasodilator Circulation 74
(1986) 222-229.
[71] S. Katsuki, W. Arnold, C. Mittal, F. Murad. Stimulation of guanylate cyclase by sodium
nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison
to the effects of sodium azide and hydroxylamine J. Cyclic Nucleotide Res. 3 (1977) 2335.
[72] C.A. Gruetter, B.K. Barry, D.B. McNamara, D.Y. Gruetter, P.J. Kadowitz, L. Ignarro.
Relaxation of bovine coronary artery and activation of coronary arterial guanylate cyclase
by nitric oxide, nitroprusside and a carcinogenic nitrosoamine J. Cyclic Nucleotide Res. 5
(1979) 211-224.
[73] R.F. Furchgott, J.V. Zawadzki. The obligatory role of endothelial cells in the relaxation of
arterial smooth muscle by acetylcholine Nature 288 (1980) 373-376.
[74] P.D. Cherry, R.F. Furchgott, J.V. Zawadzki, D. Jothianandan. Role of endothelial cells in
relaxation of isolated arteries by bradykinin Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 21062110.
[75] R.M. Palmer, A.G. Ferrige, S. Moncada. Nitric oxide release accounts for the biological
activity of endothelium-derived relaxing factor Nature 327 (1987) 524-526.
[76] L.J. Ignarro, G.M. Buga, K.S. Wood, R.E. Byrns, G. Chaudhuri. Endothelium-derived
relaxing factor produced and released from artery and vein is nitric oxide Proc. Natl.
Acad. Sci. U.S.A. 84 (1987) 9265-9269.
[77] P.L. Huang, Z. Huang, H. Mashimo, K.D. Bloch, M.A. Moskowitz, J.A. Bevan, M.C.
Fishman. Hypertension in mice lacking the gene for endothelial nitric oxide synthase
Nature 377 (1995) 239-242.
[78 ] J.E. Freedman, R. Sauter, E.M. Battinelli, K. Ault, C. Knowles, P.L. Huang, J. Loscalzo.
Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the
NOSIII gene Circ. Res. 84 (1999) 1416-1421.
[79] M. Moroi, L. Zhang, T. Yasuda, R. Virmani, H.K. Gold, M.C. Fishman, P.L. Huang.
Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in
vascular response to injury in mice J. Clin. Invest. 101 (1998) 1225-1232.
[80] D.J. Lefer, S.P. Jones, W.G. Girod, A. Baines, M.B. Grisham, A.S. Cockrell, P.L. Huang, R.
Scalia. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice Am.
J. Physiol. 276 (1999) H1943-50.
[81] E.H. Lo, H. Hara, J. Rogowska, M. Trocha, A.R. Pierce, P.L. Huang, M.C. Fishman, G.L.
Wolf, M.A. Moskowitz. Temporal correlation mapping analysis of the hemodynamic
penumbra in mutant mice deficient in endothelial nitric oxide synthase gene expression
Stroke 27 (1996) 1381-1385.
[82] S. Kashiwagi, D.N. Atochin, Q. Li, M. Schleicher, T. Pong, W.C. Sessa, P.L. Huang. eNOS
phosphorylation on serine 1176 affects insulin sensitivity and adiposity Biochem. Biophys.
Res. Commun. 431 (2013) 284-290.
[83] Q. Li, D. Atochin, S. Kashiwagi, J. Earle, A. Wang, E. Mandeville, K. Hayakawa, L.V.
d'Uscio, E.H. Lo, Z. Katusic, W. Sessa, P.L. Huang. Deficient eNOS phosphorylation is a

30

mechanism for diabetic vascular dysfunction contributing to increased stroke size Stroke
44 (2013) 3183-3188.
[84] J.B. Hibbs Jr, Z. Vavrin, R.R. Taintor. L-arginine is required for expression of the
activated macrophage effector mechanism causing selective metabolic inhibition in target
cells J. Immunol. 138 (1987) 550-565.
[85] D.J. Stuehr, C.F. Nathan. Nitric oxide. A macrophage product responsible for cytostasis
and respiratory inhibition in tumor target cells J. Exp. Med. 169 (1989) 1543-1555.
[86] D.J. Stuehr, N.S. Kwon, S.S. Gross, B.A. Thiel, R. Levi, C.F. Nathan. Synthesis of nitrogen
oxides from L-arginine by macrophage cytosol: Requirement for inducible and constitutive
components Biochem. Biophys. Res. Commun. 161 (1989) 420-426.
[87] R. Korhonen, A. Lahti, H. Kankaanranta, E. Moilanen. Nitric oxide production and
signaling in inflammation Curr. Drug Targets Inflamm. Allergy 4 (2005) 471-479.
[88] S. Mariotto, Y. Suzuki, T. Persichini, M. Colasanti, H. Suzuki, O. Cantoni. Cross-talk
between NO and arachidonic acid in inflammation Curr. Med. Chem. 14 (2007) 19401944.
[89] G.C. Brown. Nitric oxide and neuronal death Nitric Oxide 23 (2010) 153-165.
[90] E.A. Grimm, A.G. Sikora, S. Ekmekcioglu. Molecular pathways: Inflammation-associated
nitric-oxide production as a cancer-supporting redox mechanism and a potential
therapeutic target Clin. Cancer Res. 19 (2013) 5557-5563.
[91] R. Welter, L. Yu, C.A. Yu. The effects of nitric oxide on electron transport complexes Arch.
Biochem. Biophys. 331 (1996) 9-14.
[92] P. Krippeit-Drews, K.D. Kroncke, S. Welker, G. Zempel, M. Roenfeldt, H.P. Ammon, F.
Lang, G. Drews. The effects of nitric oxide on the membrane potential and ionic currents
of mouse pancreatic B cells Endocrinology 136 (1995) 5363-5369.
[93] C.H. Tang, W. Wei, L. Liu. Regulation of DNA repair by S-nitrosylation Biochim. Biophys.
Acta 1820 (2012) 730-735.
[94] D.W. Reif, R.D. Simmons. Nitric oxide mediates iron release from ferritin Arch. Biochem.
Biophys. 283 (1990) 537-541.
[95] X.Q. Wei, I.G. Charles, A. Smith, J. Ure, G.J. Feng, F.P. Huang, D. Xu, W. Muller, S.
Moncada, F.Y. Liew. Altered immune responses in mice lacking inducible nitric oxide
synthase Nature 375 (1995) 408-411.
[96] J.D. MacMicking, C. Nathan, G. Hom, N. Chartrain, D.S. Fletcher, M. Trumbauer, K.
Stevens, Q.W. Xie, K. Sokol, N. Hutchinson. Altered responses to bacterial infection and
endotoxic shock in mice lacking inducible nitric oxide synthase Cell 81 (1995) 641-650.
[97] R. Gyurko, G. Boustany, P.L. Huang, A. Kantarci, T.E. Van Dyke, C.A. Genco, F.C. Gibson
3rd. Mice lacking inducible nitric oxide synthase demonstrate impaired killing of
porphyromonas gingivalis Infect. Immun. 71 (2003) 4917-4924.
[98] D.J. Scott, M.A. Hull, E.J. Cartwright, W.K. Lam, A. Tisbury, R. Poulsom, A.F. Markham, C.
Bonifer, P.L. Coletta. Lack of inducible nitric oxide synthase promotes intestinal
tumorigenesis in the apc(min/+) mouse Gastroenterology 121 (2001) 889-899.

31

[99] K.J. Armour, K.E. Armour, R.J. van't Hof, D.M. Reid, X.Q. Wei, F.Y. Liew, S.H. Ralston.
Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced
osteoporosis by suppressing bone formation and causing osteoblast apoptosis Arthritis
Rheum. 44 (2001) 2790-2796.
[100] C. Iadecola, F. Zhang, X. Xu. Inhibition of inducible nitric oxide synthase ameliorates
cerebral ischemic damage Am. J. Physiol. 268 (1995) R286-92.
[101] C. Iadecola, F. Zhang, R. Casey, M. Nagayama, M.E. Ross. Delayed reduction of ischemic
brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase
gene J. Neurosci. 17 (1997) 9157-9164.
[102] D.S. Bredt, S.H. Snyder. Nitric oxide mediates glutamate-linked enhancement of cGMP
levels in the cerebellum Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 9030-9033.
[103] J. Garthwaite, G. Garthwaite, R.M. Palmer, S. Moncada. NMDA receptor activation induces
nitric oxide synthesis from arginine in rat brain slices Eur. J. Pharmacol. 172 (1989) 413416.
[104] G.A. Bohme, C. Bon, J.M. Stutzmann, A. Doble, J.C. Blanchard. Possible involvement of
nitric oxide in long-term potentiation Eur. J. Pharmacol. 199 (1991) 379-381.
[105] E.M. Schuman, D.V. Madison. A requirement for the intercellular messenger nitric oxide in
long-term potentiation Science 254 (1991) 1503-1506.
[106] T.J. O'Dell, R.D. Hawkins, E.R. Kandel, O. Arancio. Tests of the roles of two diffusible
substances in long-term potentiation: Evidence for nitric oxide as a possible early
retrograde messenger Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 11285-11289.
[107] J.E. Haley, G.L. Wilcox, P.F. Chapman. The role of nitric oxide in hippocampal long-term
potentiation Neuron 8 (1992) 211-216.
[108] N. Hardingham, K. Fox. The role of nitric oxide and GluR1 in presynaptic and postsynaptic
components of neocortical potentiation J. Neurosci. 26 (2006) 7395-7404.
[109] M.K. Meffert, B.A. Premack, H. Schulman. Nitric oxide stimulates Ca(2+)-independent
synaptic vesicle release Neuron 12 (1994) 1235-1244.
[110] M.K. Meffert, N.C. Calakos, R.H. Scheller, H. Schulman. Nitric oxide modulates synaptic
vesicle docking fusion reactions Neuron 16 (1996) 1229-1236.
[111] K.D. Micheva, J. Buchanan, R.W. Holz, S.J. Smith. Retrograde regulation of synaptic
vesicle endocytosis and recycling Nat. Neurosci. 6 (2003) 925-932.
[112] D.P. Li, S.R. Chen, T.F. Finnegan, H.L. Pan. Signalling pathway of nitric oxide in synaptic
GABA release in the rat paraventricular nucleus J. Physiol. 554 (2004) 100-110.
[113] A. Neitz, E. Mergia, U.T. Eysel, D. Koesling, T. Mittmann. Presynaptic nitric oxide/cGMP
facilitates glutamate release via hyperpolarization-activated cyclic nucleotide-gated
channels in the hippocampus Eur. J. Neurosci. 33 (2011) 1611-1621.
[114] K. Eguchi, S. Nakanishi, H. Takagi, Z. Taoufiq, T. Takahashi. Maturation of a PKGdependent retrograde mechanism for exoendocytic coupling of synaptic vesicles Neuron 74
(2012) 517-529.

32

[115] A. Tarasenko, O. Krupko, N. Himmelreich. New insights into molecular mechanism(s)
underlying the presynaptic action of nitric oxide on GABA release Biochim. Biophys. Acta
1840 (2014) 1923-1932.
[116] C. Cserep, A. Szonyi, J.M. Veres, B. Nemeth, E. Szabadits, J. de Vente, N. Hajos, T.F.
Freund, G. Nyiri. Nitric oxide signaling modulates synaptic transmission during early
postnatal
development Cereb. Cortex 21 (2011) 2065-2074.
[117] I. Nikonenko, P. Jourdain, D. Muller. Presynaptic remodeling contributes to activitydependent synaptogenesis J. Neurosci. 23 (2003) 8498-8505.
[118] I. Nikonenko, A. Nikonenko, P. Mendez, T.V. Michurina, G. Enikolopov, D. Muller. Nitric
oxide mediates local activity-dependent excitatory synapse development Proc. Natl. Acad.
Sci. U.S.A. 110 (2013) E4142-51.
[119] V.R. Clarke, S.M. Molchanova, T. Hirvonen, T. Taira, S.E. Lauri. Activity-dependent
upregulation of presynaptic kainate receptors at immature CA3-CA1 synapses J. Neurosci.
34 (2014) 16902-16916.
[120] J.R. Steinert, C. Kopp-Scheinpflug, C. Baker, R.A. Challiss, R. Mistry, M.D. Haustein, S.J.
Griffin, H. Tong, B.P. Graham, I.D. Forsythe. Nitric oxide is a volume transmitter regulating
postsynaptic excitability at a glutamatergic synapse Neuron 60 (2008) 642-656.
[121] J.R. Steinert, S.W. Robinson, H. Tong, M.D. Haustein, C. Kopp-Scheinpflug, I.D. Forsythe.
Nitric oxide is an activity-dependent regulator of target neuron intrinsic excitability Neuron
71 (2011) 291-305.
[122] G.A. Rameau, D.S. Tukey, E.D. Garcin-Hosfield, R.F. Titcombe, C. Misra, L. Khatri, E.D.
Getzoff, E.B. Ziff. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the
NMDA receptor regulates AMPA receptor trafficking and neuronal cell death J. Neurosci.
27 (2007) 3445-3455.
[123] A. Almeida, J. Almeida, J.P. Bolanos, S. Moncada. Different responses of astrocytes and
neurons to nitric oxide: The role of glycolytically generated ATP in astrocyte protection
Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 15294-15299.
[124] A. Almeida, S. Moncada, J.P. Bolanos. Nitric oxide switches on glycolysis through the AMP
protein kinase and 6-phosphofructo-2-kinase pathway Nat. Cell Biol. 6 (2004) 45-51.
[125] K.S. Christopherson, B.J. Hillier, W.A. Lim, D.S. Bredt. PSD-95 assembles a ternary
complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase
PDZ domain J. Biol. Chem. 274 (1999) 27467-27473.
[126] P.L. Huang, T.M. Dawson, D.S. Bredt, S.H. Snyder, M.C. Fishman. Targeted disruption of
the neuronal nitric oxide synthase gene Cell 75 (1993) 1273-1286.
[127] R. Weitzdoerfer, H. Hoeger, E. Engidawork, M. Engelmann, N. Singewald, G. Lubec, B.
Lubec. Neuronal nitric oxide synthase knock-out mice show impaired cognitive
performance Nitric Oxide 10 (2004) 130-140.
[128] M. Juch, K.H. Smalla, T. Kahne, G. Lubec, W. Tischmeyer, E.D. Gundelfinger, M.
Engelmann. Congenital lack of nNOS impairs long-term social recognition memory and
alters the olfactory bulb proteome Neurobiol. Learn. Mem. 92 (2009) 469-484.

33

[129] J.B. Kelley, M.A. Balda, K.L. Anderson, Y. Itzhak. Impairments in fear conditioning in mice
lacking the nNOS gene Learn. Mem. 16 (2009) 371-378.
[130] S.P. Zoubovsky, V.M. Pogorelov, Y. Taniguchi, S.H. Kim, P. Yoon, E. Nwulia, A. Sawa,
M.V. Pletnikov, A. Kamiya. Working memory deficits in neuronal nitric oxide synthase
knockout mice: Potential impairments in prefrontal cortex mediated cognitive function
Biochem. Biophys. Res. Commun. 408 (2011) 707-712.
[131] V. Lev-Ram, Z. Nebyelul, M.H. Ellisman, P.L. Huang, R.Y. Tsien. Absence of cerebellar
long-term depression in mice lacking neuronal nitric oxide synthase Learn. Mem. 4 (1997)
169-177.
[132] J. Dachtler, N.R. Hardingham, S. Glazewski, N.F. Wright, E.J. Blain, K. Fox. Experiencedependent plasticity acts via GluR1 and a novel neuronal nitric oxide synthase-dependent
synaptic mechanism in adult cortex J. Neurosci. 31 (2011) 11220-11230.
[133] G. Yang, Y. Zhang, M.E. Ross, C. Iadecola. Attenuation of activity-induced increases in
cerebellar blood flow in mice lacking neuronal nitric oxide synthase Am. J. Physiol. Heart
Circ. Physiol. 285 (2003) H298-304.
[134] Z. Huang, P.L. Huang, N. Panahian, T. Dalkara, M.C. Fishman, M.A. Moskowitz. Effects of
cerebral ischemia in mice deficient in neuronal nitric oxide synthase Science 265 (1994)
1883-1885.
[135] L. Zhou, F. Li, H.B. Xu, C.X. Luo, H.Y. Wu, M.M. Zhu, W. Lu, X. Ji, Q.G. Zhou, D.Y. Zhu.
Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with
PSD-95 Nat. Med. 16 (2010) 1439-1443.
[136] R.T. Matthews, M.F. Beal, J. Fallon, K. Fedorchak, P.L. Huang, M.C. Fishman, B.T.
Hyman. MPP+ induced substantia nigra degeneration is attenuated in nNOS knockout
mice Neurobiol. Dis. 4 (1997) 114-121.
[137] W. Hu, L.S. Guan, X.B. Dang, P.Y. Ren, Y.L. Zhang. Small-molecule inhibitors at the PSD95/nNOS interface attenuate MPP+-induced neuronal injury through Sirt3 mediated
inhibition of mitochondrial dysfunction Neurochem. Int. 79 (2014) 57-64.
[138] J. Fang, T. Nakamura, D.H. Cho, Z. Gu, S.A. Lipton. S-nitrosylation of peroxiredoxin 2
promotes oxidative stress-induced neuronal cell death in parkinson's disease Proc. Natl.
Acad. Sci. U.S.A. 104 (2007) 18742-18747.
[139] K.K. Chung, B. Thomas, X. Li, O. Pletnikova, J.C. Troncoso, L. Marsh, V.L. Dawson, T.M.
Dawson. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's
protective function Science 304 (2004) 1328-1331.
[140] M. Shimizu-Sasamata, P. Bosque-Hamilton, P.L. Huang, M.A. Moskowitz, E.H. Lo.
Attenuated neurotransmitter release and spreading depression-like depolarizations after
focal ischemia in mutant mice with disrupted type I nitric oxide synthase gene J. Neurosci.
18 (1998) 9564-9571.
[141] B.J. Gibb, J. Garthwaite. Subunits of the nitric oxide receptor, soluble guanylyl cyclase,
expressed in rat brain Eur. J. Neurosci. 13 (2001) 539-544.
[142] E. Mergia, M. Russwurm, G. Zoidl, D. Koesling. Major occurrence of the new alpha2beta1
isoform of NO-sensitive guanylyl cyclase in brain Cell. Signal. 15 (2003) 189-195.

34

[143] E. Martin, V. Berka, E. Bogatenkova, F. Murad, A.L. Tsai. Ligand selectivity of soluble
guanylyl cyclase: Effect of the hydrogen-bonding tyrosine in the distal heme pocket on
binding of oxygen, nitric oxide, and carbon monoxide J. Biol. Chem. 281 (2006) 2783627845.
[144] B. Roy, E.J. Halvey, J. Garthwaite. An enzyme-linked receptor mechanism for nitric oxideactivated guanylyl cyclase J. Biol. Chem. 283 (2008) 18841-18851.
[145] O. Gileadi. Structures of soluble guanylate cyclase: Implications for regulatory mechanisms
and drug development Biochem. Soc. Trans. 42 (2014) 108-113.
[146] N. Toda, A.G. Herman. Gastrointestinal function regulation by nitrergic efferent nerves
Pharmacol. Rev. 57 (2005) 315-338.
[147] J. Garthwaite. Concepts of neural nitric oxide-mediated transmission Eur. J. Neurosci. 27
(2008) 2783-2802.
[148] K.B. Craven, W.N. Zagotta. CNG and HCN channels: Two peas, one pod Annu. Rev.
Physiol. 68 (2006) 375-401.
[149] A.T. Bender, J.A. Beavo. Cyclic nucleotide phosphodiesterases: Molecular regulation to
clinical use Pharmacol. Rev. 58 (2006) 488-520.
[150] Q. Yang, S.R. Chen, D.P. Li, H.L. Pan. Kv1.1/1.2 channels are downstream effectors of
nitric oxide on synaptic GABA release to preautonomic neurons in the paraventricular
nucleus Neuroscience 149 (2007) 315-327.
[151] S. Kakizawa, T. Yamazawa, Y. Chen, A. Ito, T. Murayama, H. Oyamada, N. Kurebayashi,
O. Sato, M. Watanabe, N. Mori, K. Oguchi, T. Sakurai, H. Takeshima, N. Saito, M. Iino.
Nitric oxide-induced calcium release via ryanodine receptors regulates neuronal function
Embo J. 31 (2012) 417-428.
[152] S. Wang, A.G. Teschemacher, J.F. Paton, S. Kasparov. Mechanism of nitric oxide action
on inhibitory GABAergic signaling within the nucleus tractus solitarii Faseb J. 20 (2006)
1537-1539.
[153] T. Kleppisch, A. Pfeifer, P. Klatt, P. Ruth, A. Montkowski, R. Fassler, F. Hofmann. Longterm potentiation in the hippocampal CA1 region of mice lacking cGMP-dependent kinases
is normal and susceptible to inhibition of nitric oxide synthase J. Neurosci. 19 (1999) 48-55.
[154] S. Jacoby, R.E. Sims, N.A. Hartell. Nitric oxide is required for the induction and
heterosynaptic spread of long-term potentiation in rat cerebellar slices J. Physiol. 535
(2001) 825-839.
[155] V. Lev-Ram, S.T. Wong, D.R. Storm, R.Y. Tsien. A new form of cerebellar long-term
potentiationis postsynaptic and depends on nitric oxide but not cAMP Proc. Natl. Acad. Sci.
U.S.A. 99 (2002) 8389-8393.
[156] T. Kleppisch, W. Wolfsgruber, S. Feil, R. Allmann, C.T. Wotjak, S. Goebbels, K.A. Nave, F.
Hofmann, R. Feil. Hippocampal cGMP-dependent protein kinase I supports an age- and
protein synthesis-dependent component of long-term potentiation but is not essential for
spatial reference and contextual memory J. Neurosci. 23 (2003) 6005-6012.
[157] H.S. Tasker, H.O. Jones. The action of mercaptans on acid chlorides (Part II): The acid
chlorides of phosphorus, sulphur, and nitrogen J. Chem. Soc., Trans. 95 (1909) 1910-1918.

35

[158] L.J. Ignarro, C.A. Gruetter. Requirement of thiols for activation of coronary arterial
guanylate cyclase by glyceryl trinitrate and sodium nitrite: Possible involvement of Snitrosothiols Biochim. Biophys. Acta 631 (1980) 221-231.
[159] L.J. Ignarro, H. Lippton, J.C. Edwards, W.H. Baricos, A.L. Hyman, P.J. Kadowitz, C.A.
Gruetter. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites,
nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiols as active
intermediates J. Pharmacol. Exp. Ther. 218 (1981) 739-749.
[160] E.A. Kowaluk, H.L. Fung. Spontaneous liberation of nitric oxide cannot account for in vitro
vascular relaxation by S-nitrosothiols J. Pharmacol. Exp. Ther. 255 (1990) 1256-1264.
[161] J.S. Stamler, O. Jaraki, J. Osborne, D.I. Simon, J. Keaney, J. Vita, D. Singel, C.R. Valeri, J.
Loscalzo. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of
serum albumin Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 7674-7677.
[162] D.A. Vitturi, L. Minarrieta, S.R. Salvatore, E.M. Postlethwait, M. Fazzari, G. Ferrer-Sueta,
J.R. Lancaster Jr, B.A. Freeman, F.J. Schopfer. Convergence of biological nitration and
nitrosation via symmetrical nitrous anhydride Nat. Chem. Biol. 11 (2015) 504-510.
[163] H.H. Awad, D.M. Stanbury. Autoxidation of NO in aqueous solution Int J Chem Kinet 25
(1993) 375-381.
[164] S. Goldstein, G. Czapski. The reaction of NO. with O2.- and HO2.: A pulse radiolysis study
Free Radic. Biol. Med. 19 (1995) 505-510.
[165] J.R. Lancaster Jr. Nitroxidative, nitrosative, and nitrative stress: Kinetic predictions of
reactive nitrogen species chemistry under biological conditions Chem. Res. Toxicol. 19
(2006) 1160-1174.
[166] C.H. Lim, P.C. Dedon, W.M. Deen. Kinetic analysis of intracellular concentrations of
reactive nitrogen species Chem. Res. Toxicol. 21 (2008) 2134-2147.
[167] X. Liu, M.J. Miller, M.S. Joshi, H. Sadowska-Krowicka, D.A. Clark, J.R. Lancaster Jr.
Diffusion-limited reaction of free nitric oxide with erythrocytes J. Biol. Chem. 273 (1998)
18709-18713.
[168] M.N. Moller, Q. Li, J.R. Lancaster Jr, A. Denicola. Acceleration of nitric oxide autoxidation
and nitrosation by membranes IUBMB Life 59 (2007) 243-248.
[169] M.N. Moller, Q. Li, D.A. Vitturi, J.M. Robinson, J.R. Lancaster Jr, A. Denicola. Membrane
"lens" effect: Focusing the formation of reactive nitrogen oxides from the *NO/O2 reaction
Chem. Res. Toxicol. 20 (2007) 709-714.
[170] A. Martinez-Ruiz, I.M. Araujo, A. Izquierdo-Alvarez, P. Hernansanz-Agustin, S. Lamas, J.M.
Serrador. Specificity in S-nitrosylation: A short-range mechanism for NO signaling?
Antioxid. Redox Signal. 19 (2013) 1220-1235.
[171] D. Jourd'heuil, F.L. Jourd'heuil, M. Feelisch. Oxidation and nitrosation of thiols at low
micromolar exposure to nitric oxide. evidence for a free radical mechanism J. Biol. Chem.
278 (2003) 15720-15726.
[172] R.S. Wade, C.E. Castro. Redox reactivity of iron(III) porphyrins and heme proteins with
nitric oxide. nitrosyl transfer to carbon, oxygen, nitrogen, and sulfur Chem. Res. Toxicol. 3
(1990) 289-291.

36

[173] A.J. Gow, J.S. Stamler. Reactions between nitric oxide and haemoglobin under
physiological conditions Nature 391 (1998) 169-173.
[174] K. Inoue, T. Akaike, Y. Miyamoto, T. Okamoto, T. Sawa, M. Otagiri, S. Suzuki, T.
Yoshimura, H. Maeda. Nitrosothiol formation catalyzed by ceruloplasmin. Implication for
cytoprotective mechanism in vivo J. Biol. Chem. 274 (1999) 27069-27075.
[175] M. Boese, P.I. Mordvintcev, A.F. Vanin, R. Busse, A. Mulsch. S-nitrosation of serum
albumin by dinitrosyl-iron complex J. Biol. Chem. 270 (1995) 29244-29249.
[176] C.A. Bosworth, J.C. Toledo Jr, J.W. Zmijewski, Q. Li, J.R. Lancaster Jr. Dinitrosyliron
complexes and the mechanism(s) of cellular protein nitrosothiol formation from nitric oxide
Proc. Natl. Acad. Sci. U.S.A. 106 (2009) 4671-4676.
[177] J.R. Hickok, S. Sahni, H. Shen, A. Arvind, C. Antoniou, L.W. Fung, D.D. Thomas.
Dinitrosyliron complexes are the most abundant nitric oxide-derived cellular adduct:
Biological parameters of assembly and disappearance Free Radic. Biol. Med. 51 (2011)
1558-1566.
[178] M.A. Mansoor, A.M. Svardal, P.M. Ueland. Determination of the in vivo redox status of
cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma Anal. Biochem.
200 (1992) 218-229.
[179] D. Tsikas, J. Sandmann, D. Holzberg, P. Pantazis, M. Raida, J.C. Frolich. Determination of
S- nitrosoglutathione in human and rat plasma by high-performance liquid chromatography
with fluorescence and ultraviolet absorbance detection after precolumn derivatization with
o-phthalaldehyde Anal. Biochem. 273 (1999) 32-40.
[180] Y. Zhang, N. Hogg. S-nitrosothiols: Cellular formation and transport Free Radic. Biol. Med.
38 (2005) 831-838.
[181] D.A. Mitchell, M.A. Marletta. Thioredoxin catalyzes the S-nitrosation of the caspase-3
active site cysteine Nat. Chem. Biol. 1 (2005) 154-158.
[182] A.J. Gow, D.G. Buerk, H. Ischiropoulos. A novel reaction mechanism for the formation of Snitrosothiol in vivo J. Biol. Chem. 272 (1997) 2841-2845.
[183] L. Liu, A. Hausladen, M. Zeng, L. Que, J. Heitman, J.S. Stamler. A metabolic enzyme for Snitrosothiol conserved from bacteria to humans Nature 410 (2001) 490-494.
[184] R.L. Bateman, D. Rauh, B. Tavshanjian, K.M. Shokat. Human carbonyl reductase 1 is an
S-nitrosoglutathione reductase J. Biol. Chem. 283 (2008) 35756-35762.
[185] M. Benhar, M.T. Forrester, D.T. Hess, J.S. Stamler. Regulated protein denitrosylation by
cytosolic and mitochondrial thioredoxins Science 320 (2008) 1050-1054.
[186] K.A. Broniowska, A.R. Diers, N. Hogg. S-nitrosoglutathione Biochim. Biophys. Acta 1830
(2013) 3173-3181.
[187] J.B. Mannick, A. Hausladen, L. Liu, D.T. Hess, M. Zeng, Q.X. Miao, L.S. Kane, A.J. Gow,
J.S. Stamler. Fas-induced caspase denitrosylation Science 284 (1999) 651-654.
[188] N. Sen, M.R. Hara, A.S. Ahmad, M.B. Cascio, A. Kamiya, J.T. Ehmsen, N. Agrawal, L.
Hester, S. Dore, S.H. Snyder, A. Sawa. GOSPEL: A neuroprotective protein that binds to
GAPDH upon S-nitrosylation Neuron 63 (2009) 81-91.

37

[189] J. Jia, A. Arif, F. Terenzi, B. Willard, E.F. Plow, S.L. Hazen, P.L. Fox. Target-selective
protein S-nitrosylation by sequence motif recognition Cell 159 (2014) 623-634.
[190] I. Sliskovic, A. Raturi, B. Mutus. Characterization of the S-denitrosation activity of protein
disulfide isomerase J. Biol. Chem. 280 (2005) 8733-8741.
[191] M. Trujillo, M.N. Alvarez, G. Peluffo, B.A. Freeman, R. Radi. Xanthine oxidase-mediated
decomposition of S-nitrosothiols J. Biol. Chem. 273 (1998) 7828-7834.
[192] D. Jourd'heuil, F.S. Laroux, A.M. Miles, D.A. Wink, M.B. Grisham. Effect of superoxide
dismutase on the stability of S-nitrosothiols Arch. Biochem. Biophys. 361 (1999) 323-330.
[193] Y. Hou, Z. Guo, J. Li, P.G. Wang. Seleno compounds and glutathione peroxidase catalyzed
decomposition of S-nitrosothiols Biochem. Biophys. Res. Commun. 228 (1996) 88-93.
[194] P.T. Doulias, J.L. Greene, T.M. Greco, M. Tenopoulou, S.H. Seeholzer, R.L. Dunbrack, H.
Ischiropoulos. Structural profiling of endogenous S-nitrosocysteine residues reveals unique
features that accommodate diverse mechanisms for protein S-nitrosylation Proc. Natl.
Acad. Sci. U.S.A. 107 (2010) 16958-16963.
[195] D.T. Hess, A. Matsumoto, S.O. Kim, H.E. Marshall, J.S. Stamler. Protein S-nitrosylation:
Purview and parameters Nat. Rev. Mol. Cell Biol. 6 (2005) 150-166.
[196] S.M. Marino, V.N. Gladyshev. Cysteine function governs its conservation and degeneration
and restricts its utilization on protein surfaces J. Mol. Biol. 404 (2010) 902-916.
[197] A. Weichsel, E.M. Maes, J.F. Andersen, J.G. Valenzuela, T.K. Shokhireva, F.A. Walker,
W.R. Montfort. Heme-assisted S-nitrosation of a proximal thiolate in a nitric oxide transport
protein Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 594-599.
[198] T.M. Greco, R. Hodara, I. Parastatidis, H.F. Heijnen, M.K. Dennehy, D.C. Liebler, H.
Ischiropoulos. Identification of S-nitrosylation motifs by site-specific mapping of the Snitrosocysteine proteome in human vascular smooth muscle cells Proc. Natl. Acad. Sci.
U.S.A. 103 (2006) 7420-7425.
[199] P. Lane, G. Hao, S.S. Gross. S-nitrosylation is emerging as a specific and fundamental
posttranslational protein modification: Head-to-head comparison with O-phosphorylation
Sci. STKE 2001 (2001) re1.
[200] D.T. Hess, J.S. Stamler. Regulation by S-nitrosylation of protein post-translational
modification J. Biol. Chem. 287 (2012) 4411-4418.
[201] M.D. Kornberg, N. Sen, M.R. Hara, K.R. Juluri, J.V. Nguyen, A.M. Snowman, L. Law, L.D.
Hester, S.H. Snyder. GAPDH mediates nitrosylation of nuclear proteins Nat. Cell Biol. 12
(2010) 1094-1100.
[202] N. Numajiri, K. Takasawa, T. Nishiya, H. Tanaka, K. Ohno, W. Hayakawa, M. Asada, H.
Matsuda, K. Azumi, H. Kamata, T. Nakamura, H. Hara, M. Minami, S.A. Lipton, T. Uehara.
On-off system for PI3-kinase-akt signaling through S-nitrosylation of phosphatase with
sequence homology to tensin (PTEN) Proc. Natl. Acad. Sci. U.S.A. 108 (2011) 1034910354.
[203] A. Riccio, R.S. Alvania, B.E. Lonze, N. Ramanan, T. Kim, Y. Huang, T.M. Dawson, S.H.
Snyder, D.D. Ginty. A nitric oxide signaling pathway controls CREB-mediated gene
expression in neurons Mol. Cell 21 (2006) 283-294.

38

[204] N. Sen, S.H. Snyder. Neurotrophin-mediated degradation of histone methyltransferase by
S-nitrosylation cascade regulates neuronal differentiation Proc. Natl. Acad. Sci. U.S.A. 108
(2011) 20178-20183.
[205] H. Stroissnigg, A. Trancikova, L. Descovich, J. Fuhrmann, W. Kutschera, J. Kostan, A.
Meixner, F. Nothias, F. Propst. S-nitrosylation of microtubule-associated protein 1B
mediates nitric-oxide-induced axon retraction Nat. Cell Biol. 9 (2007) 1035-1045.
[206] U. Frey, R.G. Morris. Synaptic tagging and long-term potentiation Nature 385 (1997) 533536.
[207] Y.B. Choi, L. Tenneti, D.A. Le, J. Ortiz, G. Bai, H.S. Chen, S.A. Lipton. Molecular basis of
NMDA receptor-coupled ion channel modulation by S-nitrosylation Nat. Neurosci. 3 (2000)
15-21.
[208] B. Selvakumar, M.A. Jenkins, N.K. Hussain, R.L. Huganir, S.F. Traynelis, S.H. Snyder. Snitrosylation of AMPA receptor GluA1 regulates phosphorylation, single-channel
conductance, and endocytosis Proc. Natl. Acad. Sci. U.S.A. 110 (2013) 1077-1082.
[209] Y. Huang, H.Y. Man, Y. Sekine-Aizawa, Y. Han, K. Juluri, H. Luo, J. Cheah, C. Lowenstein,
R.L. Huganir, S.H. Snyder. S-nitrosylation of N-ethylmaleimide sensitive factor mediates
surface expression of AMPA receptors Neuron 46 (2005) 533-540.
[210] B. Selvakumar, R.L. Huganir, S.H. Snyder. S-nitrosylation of stargazin regulates surface
expression of AMPA-glutamate neurotransmitter receptors Proc. Natl. Acad. Sci. U.S.A.
106 (2009) 16440-16445.
[211] B. Dejanovic, G. Schwarz. Neuronal nitric oxide synthase-dependent S-nitrosylation of
gephyrin regulates gephyrin clustering at GABAergic synapses J. Neurosci. 34 (2014)
7763-7768.
[212] A.K. Mustafa, M. Kumar, B. Selvakumar, G.P. Ho, J.T. Ehmsen, R.K. Barrow, L.M. Amzel,
S.H. Snyder. Nitric oxide S-nitrosylates serine racemase, mediating feedback inhibition of
D-serine formation Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 2950-2955.
[213] T. Papouin, L. Ladepeche, J. Ruel, S. Sacchi, M. Labasque, M. Hanini, L. Groc, L.
Pollegioni, J.P. Mothet, S.H. Oliet. Synaptic and extrasynaptic NMDA receptors are gated
by different endogenous coagonists Cell 150 (2012) 633-646.

39

CHAPTER 2

STRATEGIES AND TOOLS TO EXPLORE PROTEIN SNITROSYLATION

By

Karthik Rajua, b Paschalis-Thomas Douliasa, Margarita Tenopouloua,
Jennifer L. Greenea, c and Harry Ischiropoulosa, b, c *

(published in Biochimica et Biophysica Acta, June 2012. Volume 1820, Issue 6,
pages 684-688)

a

Department of Pediatrics and Pharmacology, Children’s Hospital of
Philadelphia Research Institute, Philadelphia, PA 19104

b

Neuroscience Graduate Group, University of Pennsylvania, Philadelphia, PA
19104
c Biochemistry

and Molecular Biophysics Graduate Group, University of
Pennsylvania, Philadelphia, PA 19104

*

Corresponding Author: Children’s Hospital of Philadelphia Research Institute,
3615 Civic Center Boulevard, Philadelphia, PA 19104
Tel: 215-590-5320
E-mail address: ischirop@mail.med.upenn.edu (H. Ischiropoulos)
40

Abstract
A biochemical pathway by which nitric oxide accomplishes functional diversity is
the specific modification of protein cysteine residues to form S-nitrosocysteine.
This post-translational modification, S-nitrosylation, impacts protein function and
location. Despite considerable advances with individual proteins, the biological
chemistry and the structural elements that govern the modification of specific
cysteine residues in vivo are vastly unknown. Moreover comprehensive studies
exploring protein signaling pathways or interrelated protein clusters that are
regulated by S-nitrosylation have not been performed on a global scale. To
provide insights to these important biological questions, sensitive, validated and
quantitative proteomic approaches are required. This review summarizes current
approaches for the global identification of S-nitrosylated proteins.
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S-nitrosylation
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S-nitrosylation of cysteine residues an important regulator of protein
function
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2.1 Introduction
Since its discovery nitric oxide has become increasingly evident as a
major regulator of physiological function. The effects of nitric oxide on physiology
are exerted primarily through two molecular mechanisms, comprised of cyclic
GMP (cGMP)-dependent signaling cascades and post-translational modification
(PTM) of proteins. Initially, nitrosylation of the heme iron in soluble guanylate
cyclase was found to activate the enzyme to generate cGMP, thereby regulating
the function of a number of cGMP-dependent signaling pathways. However, in
recent

years

the

importance

of

nitric

oxide-derived

post-translational

modifications of proteins has gained recognition as mediators of protein function.
One of these modifications, S-nitrosylation, is defined as the covalent
addition of a nitric oxide equivalent to the thiol side chain of cysteine [1]. This
modification has been shown to alter protein activity, protein-protein interactions,
and sub-cellular localization under physiological and pathological conditions [2, 3,
4, 5]. Additionally, evidence indicates that S-nitrosylation is reversible and is
regulated in a temporal and spatial sense, reminiscent of other post-translational
modifications such as phosphorylation [6, 7, 8]. Despite these indications of the
emerging significance of S-nitrosylation, little is known regarding the proximal
mechanisms of in vivo formation as well as how selectivity, in terms of directing
modification to specific cysteine residues, is achieved.

To improve our

understanding of the formation and selectivity of this post-translational
modification in vivo, global interrogation of S-nitrosoproteomes can be
exceptionally valuable.

Below we review the methodologies for the global

identification of S-nitrosylated proteins (Table 2.1), and discuss potential utilities
of proteomic-derived data.
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2.2 The Biotin Switch and Its Variations
2.2.1 The Biotin Switch
The biotin switch [9] was the first and is the most commonly used
technique for identifying S-nitrosylated proteins. Three steps constitute the basic
principles of the method: 1) initially, proteins in a purified preparation or complex
mixture are denatured by SDS (or urea, which is more amenable to downstream
mass spectrometry analysis, 10); to expose protein cysteine residues.
Subsequently, the reduced thiols in these proteins are blocked by reaction with
reagents such as methyl methanethiosulfonate (MMTS), N-ethylmaleimide
(NEM), or iodoacetic acid (IAA). 2) Following this blocking step, S-nitrosylated cysteine residues are selectively reduced by treatment with ascorbate. 3) The
ascorbate-reduced cysteine residues are then reacted with biotin-HPDP (N-[6(biotinamido)hexyl]-3’-(2’-pyridyldithio)-propionamide). The conjugation of these
protein cysteine residues to biotin permits enrichment of the modified targets
from a complex mixture using avidin-based affinity capture. The affinity enriched
preparations can be probed with antibodies, if the protein targets of interest are
known, or digested with trypsin and subjected to liquid chromatography tandem
mass spectrometry (LC-MS/MS). One added benefit of this method is that it is
amenable to stable isotope labeling with amino acids in cell culture (SILAC) in
order to quantitatively determine the levels of S-nitrosylation for specific cysteine
residues via mass spectrometry-based approaches [11].

2.2.2 Biotin Switch-based Peptide Identification
The original biotin-switch method did not provide the means to identify the
site(s) of modification in S-nitrosylated proteins. Identification of these sites is
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the ultimate qualifier for the unambiguous assignment of S-nitrosylated proteins.
Site-specific identification enables mutational analysis to explore the functional
role of this modification.

Two similar approaches to achieve site-specific

identification of modified cysteine residues have been developed based on the
biotin switch [12, 13]. For both methods, proteins are first digested with trypsin
and the resultant peptides are incubated with avidin or its derivatives. These
peptides are then eluted and subjected to LC-MS/MS to determine the site of
modification.

2.2.3 The His-Tag Switch
Since the original description of the biotin switch methods, several
variations have been developed. One of these variants, the His-Tag switch, [14]
begins with the blocking of free thiols by NEM, followed by ascorbate reduction of
S-nitrosylated cysteine residues. It diverges from the biotin switch, however, by
treating these ascorbate-reduced cysteines with a conjugate of iodoacetate and a
His-containing peptide.

Proteins containing this “His-tag” are then enriched

through affinity chromatography in a nickel column, after which they are eluted
and subjected to 1-dimensional (1D) gel electrophoresis. In-gel digestion with
trypsin is then performed. Trypsin, in addition to cleaving the peptide backbone
also facilitates cleavage of part of the alkylating agent, resulting in a mass
increase of the cysteine residue by 271.12 Da, which is used to identify the
modified peptide by LC-MS/MS. This method thus provides another approach for
identifying the site(s) of modification in S-nitrosylated proteins.
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2.2.4

Fluorescence-based Detection (DyLight, Cyanine, and AMCA-based

Methods)
Another method based on the biotin switch relies on 2-dimensional
differential gel electrophoresis (2D-DIGE, 15). The initial steps of this approach
are identical to the biotin switch.

After blocking by MMTS (or NEM) S-

nitrosylated-cysteine residues are reduced by ascorbate. However, instead of
biotin-HPDP, a set of DyLight maleimide sulfhydryl reactive fluorescent
compounds are used to react with the newly reduced cysteine residues.
Individual samples labeled with a DyLight fluorescent compound are separated
on a 2D gel. By comparing the fluorescent intensity of a single spot in the gel, a
relative assessment of protein S-nitrosylation levels can be made.

Another

variation of this method employs fluorescent cyanine maleimide sulfhydryl
reactive compounds instead of the DyLight compounds [16].
An additional iteration of this “fluorescence switch” utilizes 7-amino-4methyl coumarin-3-acetic-acid (AMCA)-HPDP to label S-nitrosylated cysteine
residues after ascorbate reduction [17]. In this method, samples are resolved on
either 1D or 2D gels after labeling. Subsequently, the gel is subjected to UV
illumination, which activates the AMCA fluorophore and allows it to be directly
visualized.

All three versions of the “fluorescence switch” method allow for

relative quantification of S-nitrosylation levels of proteins between samples
through comparison of fluorescent intensities. However, in each case the site(s)
of S-nitrosylation in specific proteins remains elusive, thereby rendering further
studies of the functional impact of this modification challenging.
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2.2.5 d-Switch
In addition to the capabilities offered by a combination of SILAC labeling
and the biotin switch, another quantitative method was developed and tested in a
purified protein preparation [18]. In this technique, reduced cysteine residues in
recombinant glutathione S-transferase P1 (GST-P1) are labeled with NEM. Snitrosylated cysteine residues in GST-P1 are then subjected to ascorbate
reduction, followed by treatment with deuterated (d5)-NEM and in-gel trypsin
digestion. Mass spectrometry is then used to determine the relative amounts of
peptides containing only d5-NEM versus those containing both d5-NEM and NEM,
providing a quantitative assessment of S-nitrosylation.

2.2.6 SNO-RAC
Recently, another approach was developed by Stamler and colleagues to
enrich for S-nitrosylated proteins from a complex mixture [19]. Referred to as
“SNO-RAC,” this method relies on the conjugation of reduced cysteine residues
to a solid support, such as thiopropyl sepharose. The first two steps of the
protocol are identical to the biotin switch.

However, the ascorbate-reduced

cysteine residues are incubated with thiol-reactive resins, resulting in a covalent
disulfide linkage.

At this point, the proteins can be eluted and analyzed by

western blotting. Alternatively, the disulfide linkage allows for on-resin trypsin
digestion of bound proteins, resulting in site-specific identification of modified
cysteine residues by LC-MS/MS. Compared to the traditional biotin switch, SNORAC has a better sensitivity for proteins with higher mass (>100 KDa). When
combined with iTRAQ labeling, it can also report on the S-nitrosylation/denitrosylation of specific cysteine residues on a global scale [20].
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2.2.7 Overview of the Biotin Switch-based Methods
Application of the biotin switch method and its various iterations to the
identification of endogenously S-nitrosylated proteins (defined here as proteins in
cell lysate or tissue homogenate without nitric oxide or trans-nitrosylating donor
treatment) has yielded 135 targets from multiple organs and cell types. Within
this subset of proteins, 82 sites have been reported from 63 proteins, illustrating
the importance of the biotin switch in exploring the S-nitrosoproteome. However,
three potential issues have been discussed with regard to these methods. First,
the efficiency/sensitivity of this assay relies on complete blocking of reduced
cysteine residues. Incomplete blocking will result in false identification, which
can be minimized by the inclusion of negative controls such as pretreatment with
ultraviolet (UV) photolysis or dithiothreitol (DTT).

Second, the efficiency of

ascorbate reduction has been questioned [21, 22, 23], suggesting decreased
sensitivity of the method.

The concerns over ascorbate reduction are

compounded by its potential ability to reduce disulfides [24, 25], leading to false
identification. Again, the inclusion of negative controls (listed above) as well as
samples not treated with ascorbate can be employed. Alternatively, sinapinic
acid has been used to treat cell lysates in place of ascorbate as a more selective
method of reducing S-nitrosylated cysteine residues [26].

Third, there is the

possibility of disulfide exchange after ascorbate reduction, leading to false
identification of modified cysteine residues [20]. The use of methods that rely on
a direct reaction with S-nitrosylated residues without requiring ascorbate
reduction may overcome this concern.

Taken together, these potential

methodological challenges stimulated the development of alternative approaches
for exploring the S-nitrosoproteome.
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2.3 Direct Detection of S-nitrosylation by Mass Spectrometry
Theoretically, many of the concerns noted with the biotin switch and other
chemical derivatizations can be avoided by direct detection of S-nitrosocysteine
by mass spectrometry. In practice, such an approach remains challenging and
has been possible primarily for isolated proteins. Certain MS approaches such
as matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS,
where the energy needed for peptide ionization also causes the loss of nitric
oxide from the cysteine residues, can be employed. The reduction in mass by 29
Da in peptides after ionization is then diagnostic of S-nitrosylated sites. Within
the last five years, a few groups [27, 28] have been able to directly identify Snitrosylated cysteine residues by electrospray ionization quadrupole time-of-flight
(ESI-QTOF) MS. However, such investigations were limited to synthetic proteins
and/or peptides, or were only able to identify a few sites of S-nitrosylation from a
complex mixture, rendering them unsuitable in their current form to proteomewide identification of S-nitrosylated protein targets.

2.4 Gold Nanoparticle-based Enrichment
A method that relies on a direct reaction of S-nitrosocysteine residues with
gold nanoparticles (AuNPs) has been developed for identifying sites of Snitrosylation in purified protein preparations [29].

In this method, reduced

cysteine residues are initially alkylated by iodoacetamide (IAM), after which the
protein is subjected to proteolysis.

Following this digestion, peptides are

incubated with AuNPs to selectively react with the S-nitrosylated cysteine
residues, generating free nitric oxide and peptides conjugated to the AuNPs.
The nanoparticles are then treated with DTT to elute bound peptides, which are
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subsequently analyzed by mass spectrometry to identify sites of modification.
Despite the potential advantages offered by this method, two drawbacks exist.
First, the AuNPs react with both S-nitrosylated and S-glutathionylated cysteines,
providing a challenge for absolute assignment of specific post-translational
modifications to these residues. Second, this approach has not yet been applied
to complex mixtures. Nonetheless, it holds excellent promise for site-specific
identification of modified cysteine residues in S-nitrosylated proteins.

2.5 Phosphine-based Direct Labeling of S-Nitrosylated Proteins
To overcome the reliance of previous methods on the complete blocking
of reduced cysteine residues (either by MMTS, NEM, or other reagents), Zhang
and colleagues [30] introduced another approach to directly label S-nitrosylated
cysteine residues in cell extracts.

For this particular method, S-nitrosylated

cysteine residues are reductively ligated (in the presence of water) with a biotinlabeled phosphine substrate, resulting in the generation of a sulfenamide product
and thiolate. The sulfenamide and thiolate then spontaneously react to provide a
stable disulfide (conjugated to biotin) at the formerly S-nitrosylated cysteine
residue. Avidin-based enrichment of these labeled proteins is performed, and
captured proteins are then resolved on a 1D gel. This particular approach is
advantageous in its reactive specificity toward S-nitrosylated cysteine residues in
the absence of blocking. Following the introduction of this method, a number of
phosphine-based compounds have been developed that directly react with Snitrosylated -cysteine residues [31, 32, 33]. Although these approaches have yet
to identify endogenously modified sites, these compounds offer intriguing
possibilities to explore protein S-nitrosylation in vivo.
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2.6 Organomercury-Based Capture
After considering some of the limitations inherent in the biotin switch
technique and its successors, we introduced novel complementary methods for
capturing S-nitrosylated proteins and identifying their sites of modification [34]. In
this protocol, phenylmercury compounds (either conjugated to an agarose solid
support or to polyethylene glycol-biotin) react directly with S-nitrosocysteine
residues to form a stable thiol-mercury bond [35]. The first step of this procedure
is the same as that of the biotin switch. Following the blocking step, proteins are
incubated with either the organomercury-conjugated resin (MRC) or a soluble
phenylmercury-polyethyleneglycol-biotin (mPEGb) compound. After formation of
the thiol-mercury bond, a number of options are available.

S-nitrosylated

proteins can be enriched by either the MRC approach or by avidin-based affinity
capture (for mPEGb), and eluted using beta-mercaptoethanol to reduce the thiolmercury bond. Eluted proteins are then subjected to 1D gel electrophoresis, ingel trypsin digestion, and LC-MS/MS analysis. In order to identify the specific
cysteine residues modified by S-nitrosylation, a slightly altered protocol is
applied.

After incubation of blocked proteins with the phenylmercury-based

reagents, proteins are then digested with trypsin on-resin or in-solution. The
resultant peptides are either eluted with mild performic acid to oxidize the
cysteine in the thiol-mercury bond to cysteic acid (for the MRC approach), or
subjected to a combination of avidin-based affinity capture and performic acid
oxidation. In both cases, the cysteic acid generated in captured peptides is used
as the MS signature to identify the cysteine modified by S-nitrosylation.
Application of these methods yielded 328 endogenous sites of S-nitrosylation in
192 proteins in the wild-type mouse liver [34]. The method relies on the inclusion
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of negative controls and the reporting of the percentage of peptides identified as
false positives (those shared between negative controls and experimental
samples).
Advantages of this approach include the fact that it circumvents the
ascorbate reduction step. Additionally, it provides an opportunity to pinpoint the
modified cysteine residue using the MS/MS signature of the cysteic acid (C+48).
Since both proteins and peptides are identified independently, the peptides can
be matched to the proteins and thus not rely on a single peptide for protein
identification, as in previous methods [12, 13].

2.7 Overview of mass-spectrometry-based methodologies for detection of
S-nitrosylated proteins
As with any other PTM-based proteomic studies, there are some potential
caveats associated with global analyses of in vivo S-nitrosylated proteins. (1) Up
to this point, only a few methods afford sensitivity for in vivo detection, and often
investigators rely on the induction of S-nitrosylation by applying exogenous nitric
oxide donors or trans-nitrosylating agents to cells and protein preparations.
Unfortunately, such studies provide only putative sites of modification, not
necessarily those modified in vivo [36]. (2) Some methods, but not all, do not
provide the site of modification. The identification of the site not only provides
confidence for the correct identification of the protein but also enables follow-up
studies, such as mutational analysis, to explore biological function. (3) Negative
controls and the reporting of false identification rate (FIR) must be routinely
evaluated. (4) We must also consider the possibility that even a method which
identifies the sites of modification, with appropriate negative controls and low
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FIR, may still only report a subset of the modified proteins that are either most
abundant or more stable. Despite these limitations, it is still worthwhile to pursue
inquiries into the S-nitrosoproteome, if only to provide more information about the
structural and functional importance of this modification in vivo.

2.8 Conclusions
Compared

to

widespread

studies

of

PTMs

such

as

protein

phosphorylation, glycosylation, or even acetylation, the field of S-nitrosylation
represents relatively uncharted territory. Within the last few years, however, this
area of research has become quite prominent due to improvements in the
detection of S-nitrosylated cysteine residues. By applying mass spectrometrybased proteomics, a greater appreciation of the biological significance of this
modification is emerging. Additional work is needed to improve the sensitivity of
these methods.

Armed with sensitive and specific techniques, the S-

nitrosoproteome of multiple organs and/or cell types can be investigated. The
rich data from such studies can be analyzed in a variety of ways. Structurally, it
can reveal significant new insights on elements that guide the selectivity of the
modification.

Additionally, it can also provide clues to potential biochemical

reactions that derive the modification as well as explore the relative stability of
different sites of modification. Functional analyses can uncover pathways and
functional clusters of S-nitrosylated proteins, as well as their cellular location(s)
[37], allowing for development of novel hypotheses that can be tested using more
targeted approaches.
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Table 2.1
Method
1) Biotin Switch Technique
(BST):
The original method and
several variations
thereafter:
-Detergent-free BST
-SNOSID
-d-Switch
-His-Tag Switch
-Fluorescent Switch/2D-DIGE
-SNO-RAC

2) Direct Detection by ESIQTOF Mass Spectrometry

Principles
1) Blockage of free thiols with
thiosulfonate MMTS
2) Ascorbate reduction of Snitrosocysteine.
3) Reaction of ascorbategenerated free cysteine with
biotin-HPDP (or other thiolreactive compounds).
4) Enrichment of labeled proteins
or peptides.
2D-DIGE to assess relative
changes in S- nitrosylation levels.
5) Western blot or LC-MS/MS to
identify protein targets.
6) Peptide enrichment allows sitespecific identification of modified
cysteine residues.
Direct detection of SNO moiety
on modified proteins.

3) Phosphine-based
derivatization

Specific reaction of SNO moiety
on proteins with phosphine-based
compounds without blocking free
thiols.

4) Gold Nanoparticles
(AuNPs)

1) Blockage of free thiols with
IAM.
2) Enrichment of SNO-proteins
via reaction of S-nitrosocysteine
with AuNPs.
3) Trypsin digestion and elution of
bound peptides.
4) LC-MS/MS to identify sites of
modification.
1) Blockage of free thiols with
MMTS.
2) Reaction with organomercury
reagents.
3) LC-MS/MS to identify
independently protein targets and
sites of modification.

5) Organomercury-based
Affinity Enrichment
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Comments
Collectively 135
endogenously-modified
protein targets have
identified.
82 endogenous sites on 63
proteins were also identified
Proteomics applicability.
Reliance on selective
reduction of SNO moiety
prior to labeling, which has
been discussed previously
(20-26).

Site-specific identification
Limited to isolated proteins
or peptides.
Direct reaction of phosphine
compounds with S nitrosocysteine provides
selective one-step labeling
of modified residues.
Potential applicability for
mass-spectrometry-based
proteomics needs to be
explored.
Site-specific identification.
AuNP reactivity toward Snitrosocysteine and Sglutathionylated cysteine
residues prevents absolute
assignment of correct PTM.
Applied only to purified
protein preparations, not
complex mixtures.
Site-specific identification of
328 endogenous Snitrosylated peptides in 192
proteins in a single
experiment.
Reliance on
organomercury-SNO
chemistry; requires negative
controls.
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3.1 Introduction
Nitric oxide (NO) is an important physiological regulator of biological
function in multiple tissues. NO-mediated signaling contributes to synaptic
transmission and cerebrovascular coupling in the CNS (1-4). The biological
effects of NO are primarily achieved through two molecular mechanisms: (i) the
activation of soluble guanylate cyclase and downstream cGMP-dependent
signaling cascades and (ii) S-nitrosylation, the post-translational modification of
reduced cysteine residues in proteins to generate S-nitrosocysteine. Protein Snitrosylation has emerged as a vital mediator of protein function and signaling.
The neuronal isoform of nitric oxide synthase (nNOS) produces NO in the
brain. Mice with a genetic deletion of nNOS (nNOS-/-) demonstrate various
phenotypic insufficiencies (5), including deficits in several forms of memory (6-9).
Furthermore, these mice have decreased presynaptic/postsynaptic excitability
(10-11) and synaptic plasticity (12-14), effects that may be due to impaired
glutamatergic neurotransmission. Additionally, nNOS-/- mice exhibit reduced
neurodegeneration after cerebral ischemia, which may be because of reduced
glutamate excitotoxicity (15-16). Therefore nNOS-derived NO could affect
synaptic activity by regulating glutamate availability. Many of the effects of NO
on neurotransmission occur independently of cGMP activation (17-19),
suggesting another mechanism for NO-dependent regulation of
neurotransmission.
Protein S-nitrosylation is an alternative biochemical and molecular
pathway by which NO could influence neurotransmission in the CNS (20).
Selective protein S-nitrosylation has been linked to a few postsynaptic processes
including the regulation of NMDA receptor and AMPA receptor activity, synaptic
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targeting of PSD-95, gephyrin clustering at GABAergic synapses, surface
expression of AMPA receptors, and D-serine production (21-27). However, the
biological functions of protein S-nitrosylation in the tripartite glutamatergic
synapse remain mostly unknown. Here, we used mass spectrometry (MS)based proteomic methodologies to identify protein S-nitrosocysteine residues in
brain homogenates from wild-type, nNOS-/- and eNOS-/- mice. When coupled
with metabolomic profiling, enzyme activity measurements, and site-directed
mutagenesis, the proteomic data indicates that reversible protein S-nitrosylation
regulates glutamate uptake, metabolism, conversion to glutamine, and
glutamatergic transmission.

3.2 Results
Ontological analysis of brain S-nitrosylated proteins
Mass spectrometric analysis of endogenous S-nitrosylated proteins using
organomercury-based enrichment approaches (28-30) unearthed 269 sites in
136 proteins in wild-type mouse brain, 135 sites in 95 proteins in eNOS-/- brain,
and 71 sites in 53 proteins in nNOS-/- brain (Fig. 1A and Table 3.1). The
reduction in the S-nitrosylation of residues and proteins in nNOS-/- (74%) and
eNOS-/- mice (50%) implied that both NOS isoforms contributed substantially to
endogenous protein S-nitrosylation (Fig. 2). To place these observations in
biological context, we performed gene ontology analysis. First we constructed a
reference mouse brain proteome consisting of 7,025 proteins curated from
previously published reports (31-34) and our experimental data. Using this
reference proteome as a background, we performed computational analysis
using WebGestalt (35) and identified several molecular pathways and cellular
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processes in which S-nitrosylated proteins were significantly enriched in the wildtype brain (Fig. 1B and 3). The computed ratio of enrichment for the top five
pathways was similar between wild-type and eNOS-/- brains but was reduced in
nNOS-/- brains (Fig. 1B). For example, the molecular processes associated with
the regulation of neurotransmitter levels showed a 67% reduction in nNOS-/brains, a finding consistent with previous descriptions of synaptic deficits in the
nNOS-/- mice (6-14). Within the regulation of neurotransmitter level pathway we
mapped S-nitrosocysteine residues in four proteins: excitatory amino acid
transporter 2, glutamate dehydrogenase, mitochondrial aspartate
aminotransferase, and glutamine synthetase (Fig. 1C). The first three proteins
were S-nitrosylated in wild-type and eNOS-/-mice, but not in nNOS-/-mice,
whereas glutamine synthetase showed reduced S-nitrosylation in nNOS-/- mice
as compared to wild-type and eNOS-/- mice (Fig. 1D and Table 3.1). We
confirmed the mass spectrometric-based identification of these S-nitrosylated
proteins by Western blotting (Fig. 1D), and quantified the fraction of each protein
modified by S-nitrosylation in wild-type brain (Fig. 1E). These four proteins are
major contributors in the glutamate/glutamine cycle (36-39), the biological
process responsible for managing the metabolic fate and availability of glutamate
in the synapse. Overall, the proteomic and ontological analysis indicates that
proteins involved in the glutamate/glutamine cycle are selectively S-nitrosylated
by nNOS, implying a role for nitric oxide in the regulation of glutamate
metabolism.
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Figure 3.1. Proteomic Identification of Protein S-Nitrosocysteine residues and Gene Ontology Analysis of
Modified Proteins in wild-type, eNOS-/-, and nNOS-/- Mouse Brain. A) Identification of S-nitrosylated proteins and their
corresponding sites of modification in mouse brain (N = 6 mice per genotype). B) Gene ontology-based functional
clustering of S-nitrosylated proteins in each genotype. The Ratio of Enrichment (R) score is calculated as the ratio of the
observed number (O) of S-nitrosylated proteins with a specific gene ontology (GO) annotation in the WebGestalt database
to the number of annotated proteins expected (E) to be in the S-nitrosocysteine proteome. Only the top five pathways in
the wild-type mouse with the lowest p-values were considered (p < 0.01). NT = Neurotransmitter. C) Schematic of
glutamate metabolism. Proteins are denoted by their short protein names, as assigned by Uniprot: GLT1 (excitatory
amino acid transporter 2), GDH (glutamate dehydrogenase), mAspAT (mitochondrial aspartate aminotransferase), and
GS (glutamine synthetase). S-nitrosylated proteins are italicized, with the associated sites of modification indicated. Gln
= Glutamine, Glu = Glutamate, Asp = Aspartate, Ala = Alanine, α-KG = α-ketoglutarate, Cys = Cysteine. D) NOS-based
dependence of S-nitrosylation of glutamate/glutamine cycle effectors. Modified proteins (denoted as the “SNO-Fraction”)
within the aforementioned pathway were confirmed by Western blot against specific targets in all genotypes. The total
abundance of the indicated protein targets in 30 µg of total homogenate did not obviously differ between genotypes. (N =
2 mice per genotype). E) Quantification of the relative S-nitrosylated fraction for each glutamate/glutamine cycle protein in
wild-type mouse brain. Bars represent mean ± SEM (N = 3 mice).
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Figure 3.2. Reduction in the enrichment of S-nitrosylated proteins in eNOS-/- and nNOS-/- mice. Representative
colloidal blue-stained gel showing the enrichment for S-nitrosylated proteins in forebrains from wild-type (WT), eNOS-/-,
and nNOS-/- mice. Proteins were resolved by SDS-PAGE over a 4-cm distance on the gel, visualized by colloidal blue
staining and scanned using the Odyssey Infrared Imaging System. The reduced intensity of protein staining in the lanes
corresponding to eNOS-/- and nNOS-/- brain homogenates relatively to wild-type homogenate, reflects the lower number of
S-nitrosylated proteins in the brain of knockouts as compared to wild-type mice. This experiment was repeated twice with
similar results (N=2 mice per genotype).

Figure 3.3. Additional biological processes and cellular functions identified for S-nitrosylated proteins in the
mouse brain. Pathways identified by gene ontology analysis are involved in metabolic functions, including NAD/NADH
metabolism, glucose metabolism and ATP synthesis/consumption. All pathways described were among the top ten
pathways enriched in S-nitrosylated proteins (p < 0.01).
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Regulation of Glutamate/Glutamine Metabolism by Nitric Oxide
To study the effects of nNOS-derived NO and protein S-nitrosylation on
the glutamate/glutamine cycle we quantified the fractional isotopic enrichment of
glutamate-associated metabolites in acutely-isolated hippocampal slices
following treatment with [2-15N] L-glutamine (Fig. 4). Steady-state amounts of
labeled glutamate-associated metabolites were quantified by HPLC and GS-MS
approaches (40-41) under stimulatory (Mg2+-free) conditions in wild-type, eNOS-/, and nNOS-/- mice. The three genotypes showed similar total amounts of
glutamate, glutamine, aspartate, alanine and GABA (Fig. 5A), indicating a lack of
gross metabolic dysfunction. However, the ratio of intracellular glutamine to
glutamate was 30% higher in nNOS-/- mice, reflecting potential perturbations in
glutamate handling (Fig. 5B).

15N-fractional

isotopic enrichment for alanine,

aspartate, and glutamate ranging between 20-30% was significantly decreased in
nNOS-/- brain slices relative to the other two genotypes, confirming altered
glutamate allocation in nNOS-/- mice (Fig. 5C).
To further explore the influence of nNOS-derived NO on the
glutamate/glutamine cycle, we performed enzymatic assays for glutamate
dehydrogenase, mitochondrial aspartate aminotransferase and glutamine
synthetase in mitochondrial extracts and brain homogenates (Fig. 5D). The
activities of glutamate dehydrogenase and mitochondrial aspartate
aminotransferase were significantly increased in nNOS-/- mitochondrial extracts
as compared to wild-type and eNOS-/- mice (Fig. 5D). Trans-illumination of wildtype mitochondrial extracts with ultraviolet (UV) light, a treatment that effectively
eliminates NO from S-nitrosocysteine residues (42-43), increased the enzymatic
activities of glutamate dehydrogenase and mitochondrial aspartate
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aminotransferase in wild-type extracts similar to that measured in nNOS-/extracts (Fig. 5D). We used selective inhibitors GTP (for glutamate
dehydrogenase) and aminooxyacetic acid (for mitochondrial aspartate
aminotransferase) to validate the specificity of the assays. Each inhibitor
resulted in >95% loss of activity (Fig. 5D). Relative to wild-type homogenate,
glutamine synthetase activity was decreased slightly in nNOS-/- but not in eNOS-/brain homogenate (Fig. 5D). UV trans-illumination decreased the activity of GS
in wild-type homogenate (Fig. 5D). The difference in the reduction of GS activity
between nNOS-/- mice and wild-type mice exposed to UV light most likely reflects
contributions from additional nitric oxide synthase isoforms to the S-nitrosylation
of GS in vivo (Fig. 1D and Table 3.1). Exposing wild-type homogenate to the
glutamine synthetase inhibitor L-methionine sulfoximine (MSO) (44) resulted in a
>95% loss of activity (Fig. 5D). Together, metabolomic profiling and enzymatic
activity assays imply that selective nNOS-dependent S-nitrosylation of key
proteins in the glutamate/glutamine cycle regulates glutamate metabolism.

65

Figure 3.4. Identification of 15N isotopic label in glutamate-associated metabolites. The 15N isotopic label is
transferred between metabolites during specific enzymatic reactions, as depicted above. Enzymes indicated in bold
denote those identified as being S-nitrosylated.
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Figure 3.5. Analysis of the Glutamate/Glutamine Cycle in WT, eNOS-/-, and nNOS-/- Mouse Brain. A) Glutamateassociated metabolite quantification. Total metabolite concentrations were determined by HPLC and normalized to
protein content (N = 3 mice per genotype). B) Intracellular glutamine/glutamate ratios. ** P<0.01 as determined by oneway ANOVA with Tukey post-hoc analysis (N = 3 mice per genotype). C) Genotypic differences in steady-state glutamate
metabolism. 15N-based enrichment of glutamate and its associated derivatives was calculated as a percentage of total
metabolite content using GC-MS and corrected for natural 15N abundance (15N+1 MPE: molar percent excess of M+1
metabolite isotopomer). * P<0.05 compared to wild-type by one-way ANOVA with Tukey post-hoc analysis between
genotypes (N = 3 mice per genotype). D) Enzymatic activity of glutamate/glutamine effectors. Bars represent mean ±
SEM (N = 3 mice per genotype), and indicate enzymatic activity relative to that measured in untreated extracts from wildtype mice. Activities in untreated wild-type extracts: GS = 1259 ± 94 nmol/mg/hr, GDH = 120 ± 15 nmol/mg/min, mAspAT
= 238 ± 12 nmol/mg/min. WT + UV denotes extracts exposed to UV trans-illumination before assessing enzymatic
activity. WT + Inhibitor denotes extracts pre-treated with specific enzymatic inhibitors (GS = 0.5 mM MSO, GDH = 20 μM
GTP, mAspAT = 1 mM AOAA). N.D. Not detectable. *P<0.05, **P<0.01, ***P<0.001 as compared to wild-type by oneway ANOVA with Tukey post-hoc analysis.

67

Regulation of intracellular transport of glutamate by the S-Nitrosylation of
excitatory amino acid transporter 2.
Excitatory amino acid transporter 2 is the primary transporter responsible
for glutamate uptake in astrocytes of the cerebral cortex (45). Genetic deletion of
the transporter results in lethal epileptic seizures in mice, and eventually leads to
limited postnatal viability (46-47). Due to its importance in physiological synaptic
function (48), as well as its identification in the brain S-nitrosocysteine proteome,
we explored the functional consequences of excitatory amino acid transporter 2
S-nitrosylation in mouse brain synaptosomal preparations, as well as in a cell
model. We quantified sodium (Na+)-dependent glutamate uptake in freshly
prepared synaptosomes from wild-type, nNOS-/-, and eNOS-/- forebrain in the
presence or the absence of the excitatory amino acid transporter 2 inhibitor
dihydrokainate (DHK) (49). The resulting difference in uptake activity between
the two treatments (DHK-sensitive) is the glutamate uptake mediated by GLT1.
Synaptosomal DHK-sensitive glutamate uptake was increased in nNOS-/synaptosomes as compared to wild-type synaptosomes (Fig. 6A). Elimination of
NO from S-nitrosocysteine residues by pre-treatment of wild-type synaptosomes
with copper plus ascorbate (50) increased DHK-sensitive glutamate uptake,
indicating a functional regulatory role for S-nitrosylation. On the other hand,
DHK-insensitive Na+-dependent glutamate was similar in synaptosomes
prepared from the three genotypes, or in synaptosomes prepared from wild-type
mice after treatment with copper and ascorbate, suggesting that non-GLT1mediated uptake was unaffected by the altered concentrations of NO or the
elimination of S-nitrosylation (Fig. 7A). We further explored the functional effect
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of S-nitrosylation in HEK-293T cells that were transiently transfected with
plasmids expressing either the wild-type rat transporter or a double point mutant
(C373S/C562S) of the two in vivo S-nitrosylated cysteine residues. The cysteine
residue at position 562 in the rat sequence corresponds to cysteine 561 in the
mouse sequence, because rat GLT1 is one amino acid longer than the mouse
protein. To induce protein S-nitrosylation, we treated cells with a nonphysiological concentration of S-nitrosocysteine, which is taken up through the Lamino acid transport system. S-nitrosocysteine is an S-nitrosylating agent that
can transfer an NO equivalent to reduced cysteine residues in proteins (51). As
a control, cells were treated with the same concentration of cysteine. Treatment
of cells with S-nitrosocysteine resulted in S-nitrosylation of the wild-type
transporter (Fig. 6B), which correlated with decreased glutamate uptake (Fig.
6C). The C373S/C562S transporter was not S-nitrosylated in S-nitrosocysteinetreated cells (Fig. 6B), and its activity was similar to that of wild-type transporter
and was unaffected by S-nitrosocysteine treatment (Fig. 6C). Mutation of one
cysteine residue (either 373 or 562) to serine resulted in transporter activity
sensitive to S-nitrosocysteine treatment, indicating that the modification of both
cysteine residues is required for S-nitrosylation-mediated inhibition of glutamate
transport (Fig. 7B). Relative to L-cysteine treatment, exposure of cells to Snitrosocysteine did not alter the protein abundance of the wild-type or the
C373S/C562S mutant transporter (Fig. 6D-6F), but decreased the surface
abundance of both transporters by 20-25% (Fig. 6G). Kinetic analysis of GLT1mediated glutamate uptake (Fig. 7C) revealed an 81% decrease in the Km of the
wild-type transporter after S-nitrosocysteine treatment and an 84% decrease in
Vmax. Removal of S-nitrosocysteine from the media led to a gradual decrease in
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the S-nitrosylation of wild-type GLT1 that correlated with a recovery in glutamate
uptake activity (Figure 6H-6I). Overall, these data suggest that specific and
reversible S-nitrosylation of GLT1 at Cys373 and Cys562 regulates the activity of
the transporter.
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Figure 3.6. Regulation of GLT1 Function by S-Nitrosylation. All results are summarized from three mice per genotype
(A) or three independent experiments in cells (B-I), and plotted as mean ± SEM. Cells were treated with L-Cysteine (Cys)
or S-nitrosocysteine (CysNO). A) The fraction of total Na+-dependent glutamate uptake that was DHK-sensitive was
greater in synaptosomes from nNOS-/- mice or synaptosomes pre-treated with copper and ascorbate (WT + Cu/Asc) than
in untreated wild-type synaptosomes. Na+-dependent uptake in untreated synaptosomes of the indicated genotype: wildtype = 0.24 ± 0.03 nmol/mg/min, nNOS-/- = 0.26 ± 0.06 nmol/mg/min, eNOS-/- = 0.25 ± 0.04 nmol/mg/min, and WT +
Cu/Asc = 0.29 ± 0.03 nmol/mg/min. *P < 0.05 after one-way ANOVA followed by Dunnett post-hoc analysis. B-C) Snitrosylation of wild-type GLT1 in HEK-293T cells following CysNO treatment (B) correlated with decreased glutamate
uptake (C). Cys-treated wild-type GLT1 = 0.27 ± 0.03 nmol/mg/min, Cys-treated C373S/C562S GLT1 = 0.26 ± 0.04
nmol/mg/min. ****P < 0.0001 after two-way ANOVA followed by Bonferroni post-hoc analysis. D-E) Representative blots
from cell surface biotinylation assays of cells expressing wild-type GLT1 (D) and C373S/C562S GLT1 (E). L, lysate; I,
intracellular fraction; C, cell surface fraction. 5 μg of total lysate and equivalent dilutions of the other fractions were used.
T, D, and M refer to trimeric, dimeric, and monomeric GLT1 respectively. The intracellular fraction of both forms of GLT1
was increased after CysNO treatment. F) Quantification of total GLT1 abundance in cell lysate. G) Quantification of
plasma membrane abundance of GLT1 after Cys/CysNO treatment. *P<0.05, **P<0.01 as determined by ANOVA with
Bonferroni post hoc analysis. H-I) S-nitrosylation of wild-type GLT1 was reversible (H), and correlated with a recovery in
glutamate uptake (I). Wild-type GLT1 cells were exposed to Cys (CTRL) or CysNO, then to fresh media. Glutamate
uptake and S-nitrosylation of GLT1 were assessed between after CysNO exposure. *P < 0.05 after one-way ANOVA
followed by Bonferroni post-hoc analysis.
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Figure 3.7. Characterization of GLT1-independent uptake in synaptosomes and GLT1-dependent uptake in cells.
(A) DHK-insensitive Na+-dependent glutamate uptake does not differ in brain synaptosomes prepared from the three
genotypes, or in synaptosomes treated with 50 µM copper plus 500 µM ascorbate, suggesting that non-GLT1-mediated
uptake is unaffected by the altered concentrations of NO or the elimination of S-nitrosylation (N=3 mice per genotype).
(B) Glutamate uptake is inhibited by CysNO treatment in cells expressing single-cysteine mutants of GLT1 (C373S or
C562S). Cells were treated with 0.4 mM of L-Cysteine (Cys) or 0.4 mM S-nitrosocysteine (CysNO) and GLT1 mediated
update was assessed in the presence of 5 nM 3H-gluatamate. Cys-treated WT GLT1 = 0.27 ± 0.03 nmol/mg/min, Cystreated C373S GLT1 = 0.24 ± 0.04 nmol/mg/min, Cys-treated C562S GLT1 = 0.25 ± 0.02 nmol/mg/min (N=3 independent
experiments). (C) CysNO treatment of the WT transporter leads to altered kinetic parameters of GLT1-mediated
glutamate uptake. A saturation curve of Na+-dependent glutamate uptake was determined for 10-1000 μM glutamate in
cells ectopically expressing the wild-type GLT1 protein. Kinetic parameters were calculated using non-linear regression
analysis of GLT1-mediated glutamate uptake and plotted as mean ± SEM (N=3 independent experiments). Km for
glutamate for Cys-treated WT GLT1 = 293 ± 27 uM, CysNO-treated WT GLT1 = 55 ± 64 uM. Vmax for Cys-treated WT
GLT1 = 11.8 ± 0.4 nmol/mg/min, CysNO-treated WT GLT1 = 1.8 ± 0.5 nmol/mg/min.

Molecular Modeling of the Effects of S-nitrosylation
We used the crystal structure of mouse mitochondrial aspartate
aminotransferase (PDB 3PD6), human glutamate dehydrogenase (PDB 1L1F)
and human glutamine synthetase (PDB 2QC8) as templates and generated
protein structures with the specific S-nitrosylated cysteine residues. Electrostatic
73

potentials and partial atomic charges were calculated for S-nitrosylated and
unmodified cysteine residues. All three proteins are large multimeric enzymes in
which pairs of equivalent modifiable cysteine residues from different monomers
are arranged with their side chains in an antiparallel fashion across from each
other. In mitochondrial aspartate aminotransferase each cysteine residue at
position 106 between chains A and B and C and D are 26Å apart. In glutamate
dehydrogenase, each cysteine residue at position 112 between chains A and E,
B & E and C & F are 20Å apart, whereas cysteine residues 99 and 183 in GS
between the side chains are about 23Å apart. S-nitrosylation of the cysteine
residue makes the side chain significantly more polar, increasing the dipole
moment from 1.7 Debye to 5.4 Debye. This increase in polarity results in an
augmented electrostatic potential which, because of the antiparallel dipole
arrangement and the effective propagation of electrostatic potentials inside large
proteins (52-61), produces a repulsive electrostatic 'wedge' between subunits
(Fig. 8). This wedge could drive changes in the quaternary structure and provide
a plausible allosteric mechanism by which S-nitrosylation of cysteine residues
distant from substrate and cofactor binding sites modulates enzyme activity.
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Figure 3.8. S-nitrosylation augments electrostatic potential. The crystal structure of mouse mAspAT (PDB 3PD6),
human GDH (PDB 1L1F) and human GS (PDB 2QC8) were used as templates and protein structures with the specific Snitrosylated cysteine residues were generated. Electrostatic potentials and partial atomic charges were calculated for Snitrosylated (shown as SNC) and unmodified (shown as C) cysteine residues. Potential in GDH produced by unmodified
Cys112 (A) and S-nitrosyl-Cys112 (B). Potential in mAspAT from Cys106/Cys295 (C) and S-nitrosyl-Cys106/ S-nitrosyl-Cys295
(D). Potential in GS from Cys99, Cys183, Cys269, and Cys346 (E) and S-nitrosyl-Cys99, S-nitrosyl-Cys183, S-nitrosyl-Cys269,
and S-nitrosyl-Cys346 (F). Isopotential contours are shown at -1kT/e in red and +1kT/e in blue. Positions of key cysteine
residues, S-nitrosyl-cysteine residues, and binding site residues are indicated.
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3.3 Discussion
S-nitrosylation of cysteine residues represents an alternative signaling
mechanism through which nitric oxide can expand the functional diversity and
biological utility of proteins. We applied a combination of chemical enrichment
and mass spectrometric technologies to specifically map endogenous sites of Snitrosylation in wild-type, nNOS-/-, and eNOS-/- mouse forebrain. In wild-type
brain 45 sites of S-nitrosylation in 44 proteins identified by our method have been
previously reported with various biochemical and proteomic approaches. The
current study contributed 225 additional S-nitrosylation sites as well as 92
additional protein targets, expanding the known endogenous S-nitrosylated
proteins in the mouse brain. As with any enrichment method, the identification of
the endogenous sites of S-nitrosylation is limited by the relative abundance and
biological stability of S-nitrosocysteine. Despite these limitations, interrogation of
the proteomic data coupled with biochemical approaches provided evidence that
protein S-nitrosylation participates in the coordination of glutamate metabolism
and neurotransmission. Specifically, four proteins that regulate glutamate
uptake, metabolism and conversion to glutamine are functionally regulated by Snitrosylation.
Glutamate uptake through excitatory amino acid transporter 2, the major
astrocytic transporter of glutamate in the CNS, was reversibly inhibited by Snitrosylation at Cys373 and Cys562. Irreversible alkylation of Cys373 inhibits
transporter activity (62), whereas the functional role of Cys562 in the rat or Cys561
in the mouse has not been studied. Because permissive mutation of these two
cysteine residues to serine did not alter excitatory amino acid transporter 2
activity, these data suggest that both cysteine residues are not critical for function
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but that posttranslational modifications at these residues are important for
functional regulation. We speculate that the transient inhibition of the transporter
may allow for an extended period of increased glutamate concentration within the
synaptic cleft, promoting neurotransmission and synaptic strengthening. The
absence of nNOS-dependent S-nitrosylation of excitatory amino acid transporter
2 may prevent nNOS-/- mice from achieving this regulation and thereby contribute
to their phenotype of dysregulated glutamatergic transmission, synaptic plasticity
and memory (6-14).
Metabolic studies have indicated that once in astrocytes, a fraction of
glutamate (estimates vary from 50-70%) is converted to glutamine by glutamine
synthetase (63-64). The remaining glutamate in astrocytes is oxidized by
glutamate dehydrogenase and mitochondrial aspartate aminotransferase to αketoglutarate, which can then enter the TCA cycle (65-66). The metabolic
demands placed on astrocytes and neurons may determine the fraction of
glutamate that is oxidized in the TCA cycle. Our data indicate that S-nitrosylation
inhibited glutamate oxidation by glutamate dehydrogenase and mitochondrial
aspartate aminotransferase, and promoted conversion to glutamine by glutamine
synthetase (Fig. 5D). Moreover, the absence of S-nitrosylation of these enzymes
in nNOS-/- mice resulted in a higher ratio of glutamine to glutamate, consistent
with increased glutamate oxidation (Fig. 5B - 5C). The lower fraction of
glutamate converted to glutamine may contribute to the phenotype of the nNOS-/mice. Although there are disagreements on the fraction of the re-cycled
glutamate that participates in neurotransmission, genetic ablation of enzymes in
the glutamate/glutamine cycle underscore the importance of maintaining this
cycle in the CNS (67). Specifically, glutamine synthetase haploinsufficiency
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leads to increased seizure susceptibility in vivo (68), with complete deletion of the
gene associated with decreased cortical glutamine and severely limited postnatal
viability (69). Glutamate dehydrogenase deletion in vivo leads to increased
glutamine concentrations in the brain (70), whereas overexpression of the
enzyme leads to decreased synaptic plasticity and age-dependent loss of
synaptic and dendritic architecture (71). During periods of increased synaptic
activity, the effect of S-nitrosylation on the reallocation of glutamate from
oxidation to regeneration of glutamine (and subsequent glutamate) provides an
explanation for how sustained neurotransmission may be achieved in wild-type
mice but not in nNOS-/- mice. The S-nitrosylation induced alteration in
glutamate metabolism could also explain why nNOS-/- mice are protected from
cerebral ischemia (15). Our data suggests that neurons in the nNOS-/- brain
would avidly oxidize glutamate and consequently exhibit attenuation of the
ischemia-induced increase in intra-synaptic glutamate (15-17, 72) while providing
ATP for metabolic processes. The partial loss of glutamine synthetase activity in
nNOS-/- brain would hinder glutamate conversion to glutamine (an important
mechanism of glutamate disposal) but would also spare limited reserves of ATP
during an ischemic episode, since the glutamine synthetase pathway normally
consumes considerable energy (73). Collectively, S-nitrosylation of these
proteins may provide a regulatory switch between glutamate oxidation and
glutamine generation to support synaptic maintenance and glutamatergic
neurotransmission.
Finally, it is interesting to note that of the 136 proteins identified as targets
of S-nitrosylation in the wild-type mouse brain, 23 have been identified as part of
macromolecular complexes implicated in glutamate metabolism at synapses
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(74). The association of glutamate uptake and mitochondrial mobility (75), the
functional interaction between glutamate dehydrogenase-mediated glutamate
oxidation and excitatory amino acid transporter 2-mediated glutamate uptake
(76), and the data presented in figures 2 and 3 indicate that selective protein Snitrosylation may function as a synapse-specific gatekeeper of glutamate fate
during neurotransmission.
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Table 3.1: S-Nitrosocysteine Sites Identified in wild-type, eNOS -/-, and
nNOS -/- Mouse Brain
Protein name
10-formyltetrahydrofolate
dehydrogenase
14-3-3 protein theta
2',3'-cyclic-nucleotide 3'phosphodiesterase
2-oxoglutarate
dehydrogenase E1
component, mitochondrial

Uniprot
ID

Peptide sequence

X

P68254

YLAEVAC134GDDRK

X

LDEDLAGYC111RR

X

X

LELVSYFGKRPPGVLHC251TTK

X

X

TKAEQFYC395

GDTEGKK

X

PSTGLEEDVLFHIGK

X

P16330

Q60597

604

SMTC

497

NTFHKDVVVDLVC
TMGC
P61922

Acetyl-CoA
acetyltransferase,
mitochondrial

Q8QZT1

Q99KI0

YRR

LATTHSK

X

C269LEEVEDLIVKYR#

X

NKGVVLGGC467GDK

X

IHMGNC193AENTAK

X

X

VAVPSTIHC126DHLIEAQVGGEK

X

X

C410KSQFTITPGSEQIR

X

X

C592TTDHISAAGPWLK

X

Actin, cytoplasmic 1*

P60710

Actin-related protein 10

Q9QZB7

X

X

ADP/ATP translocase 1
AP-1 complex subunit
beta-1
AP-2 complex subunit
alpha-1

P48962
O35643

AIGRC380AIKVEQSAER

X

P17426

AC331NQLGQFLQHR

X

AP-2 complex subunit
beta

Q9DBG3

C129LKDEDPYVRK

X

C380AIKVEQSAER

X

SGKQSIAIDDC246TFHQC251VR

X

YIGRSGIYETRC435

X

IANDNSLNHEYLPILGLAEFRSC83ASR

X

NLDKEYLPIGGLAEFC106K#

X

ATP-citrate synthase*

P05201

P05202

295

VGAFTVVC

K#

X

X

X

X

Q03265

LYC244IYVAIGQKR

X

Q91VR2

HLIIGVSSDRGLC103GAIHSSVAK

X

Q91V92

GVTIIGPATVGGIKPGC623FK

X
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X

X

EFNGLGDC160LTK

P84091

X

X

C285DVDIRKDLYANTVLSGGTTMYPGI
ADR
C27GFAGETGPR

Aspartate
aminotransferase,
cytoplasmic
Aspartate
aminotransferase,
mitochondrial*
ATP synthase subunit
alpha, mitochondrial
ATP synthase subunit
gamma, mitochondrial

nNOS
-/-

AVQMGMSSVFFNKGENC707IAAGR

4-aminobutyrate
aminotransferase,
mitochondrial*

AP-2 complex subunit mu

eNOS
-/-

Q8R0Y6

224

Aconitate hydratase,
mitochondrial

WT

X

X

X

Calcium/calmodulindependent protein kinase
type II alpha chain
Calcium/calmodulindependent protein kinase
type II beta chain*
Citrate synthase,
mitochondrial*

Clathrin heavy chain 1*

CLIP-associating protein 2

P11798

P28652

Q9CZU6

Q68FD5

Q8BRT1

C30VKVLAGQEYAAK

X

QETVDC290LKKFNAR

X

C31VKLC35TGHEYAAK

X

X

STVASMMHRQETVEC290LKK#

X

X

GYSIPEC101QKMLPK#

X

LPC211VAAK

X

YSC359QREFALK

X

HSSLAGC151QIINYR

X

AHIAQLC617EK

X

IHEGC870EEPATHNALAK

X

X

YC909EKRDPHLAC918VAYER

X

X

C1205YDEKMYDAAK

X

X

IPRPSVSQGC534SR

X

X

X
X
X
X

X

SIRGFC141LPPHC146SR

X

X

FC254TGLTQIETLFK

X

X

LGYILTC282PSNLGTGLR

X

X

X

KHNNC63MASHLTPAVYAR

X

X

X

LGYILTC317PSNLGTGLR

X

X

X

LDRLVEPLRATC1153TTK

X

TVYFAEEVQC25EGNSFHK

X

NLDSTTVAVHGEEIYC58KSC61YGKK

X

C122SQAVYAAEK

X

X

C8DKTVYFAEK

X

X

ERLELC

X

X

DHC79VAHKLFK

X

P19536

C112PNC115GTHYKLVPHQMAH#

X

P62897

IFVQKC15AQCHTVEKGGK

X

Cytochrome c1, heme
protein, mitochondrial

Q9D0M3

Cytosolic 5'-nucleotidase
III-like protein

Q3UFY7

ARHGGEDYVFSLLTGYC219EPPTGVS
LR
C48PSSHNILDNSK

X

AHSLLC106QQR

X

D-3-phosphoglycerate
dehydrogenase

Q61753

ALVDHENVISC281PHLGASTK

X

Creatine kinase B-type

Q04447

Creatine kinase,
ubiquitous mitochondrial*

P30275

Cullin-associated NEDD8dissociated protein 1

Q6ZQ38

Cysteine and glycine-rich
protein 1
Cysteine-rich protein 2
Cytochrome b-c1 complex
subunit 6, mitochondrial*
Cytochrome c oxidase
subunit 5B, mitochondrial*
Cytochrome c, somatic

P97315

Q9DCT8
P99028

51DNRVSSR
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X

X

X

X

X

X

X

D-beta-hydroxybutyrate
dehydrogenase,
mitochondrial

Q80XN0

D-dopachrome
decarboxylase

O35215

GFLVFAGC86LMK

X

SPYC209ITK

X

TIQLNVC115NSEEVEKAVETIR

X

LC24AATATILDKPEDR

X

C23STPEEIK

X

X

AVIFC39LSADKK

X

X
X

Destrin

Q9R0P5

Dihydrolipoyl
dehydrogenase,
mitochondrial*

O08749

VC484HAHPTLSEAFR

X

Dihydropyrimidinaserelated protein 1

P97427

SHKSTVEYNIFEGMEC439HGSPLVVIS
QGK

X

SITIANQTNC248PLYVTK#

X

X

Dihydropyrimidinaserelated protein 2*

O08553

Dihydropyrimidinaserelated protein 3

Q62188

Dihydropyrimidinaserelated protein 5

Q9EQF6

DmX-like protein 2*

Dpys protein (Fragment)
Electron transfer
flavoprotein-ubiquinone
oxidoreductase,
mitochondrial
Elongation factor Tu,
mitochondrial
ES1 protein homolog,
mitochondrial

Q8BPN8

Q8K0X3
Q921G7

Q8BFR5

Q9D172

Excitatory amino acid
transporter 2

P43006

Fascin (Fragment)

D3YWW
3

Fatty acid synthase*

P19096

439

X

X

GVPRGLYDGPVC504EVSVTPK#

X

X

FIPC471SPFSDYVYKR

X

X

DSELYQVFHAC181R

X

X

C432HGVPLVTISR

X

X

THNSALEYNIFEGMEC

R#

HGNIQVSC62VEC65SNQHGR

X

C1373IAGEVAIVRDPDAGEGTKR

X

VINLSQYGPAC1504FGQEHAR#

X

LHTC1577LLTSLPPLYR

X

SC1832NPVVFSFYNYLR

X

VGC1896PVLALEVLSKIPK

X

C433HGVPLVTISR

X

VTVFAEGC247HGHLAK

X

LQINAQNC585VHC588K

X

KGDEC290ELLGHNK

X

KPIGLC174C175IAPVLAAK

X

X

HC219VKGVTEAHVDQK
NKVVTTPAFMC242ETALHHIHDGIGAM
VK
C373LEDNLGIDKR

X

X

X

X

X

X

SADC561SVEEEPWKR

X

X

LINRPIIVFRGEHGFIGC397R

X

C1084LGITVSGGIHISR

X

C1464ILLSNLSNTSHAPK

X

82

Fructose-bisphosphate
aldolase A

Fructose-bisphosphate
aldolase C

Fructose-bisphosphate
aldolase

P05064

P05063

Q9CPQ9

QLLLTADDRVNPC73IGGVILFHETLYQ
K
C150VLKIGEHTPSALAIMENANVLAR
YASIC178QQNGIVPIVEPEILPDGDHDL
KR
C202QYVTEK

Q8VED9

Glutamate decarboxylase
1

P48318

Glutamate dehydrogenase
1, mitochondrial

P26443

Glutamine synthetase*

Glyceraldehyde-3phosphate
dehydrogenase*
Glycerol-3-phosphate
dehydrogenase,
mitochondrial

P15105

P16858

Q64521

Glycogen phosphorylase,
brain form*

Q8CI94

Guanine nucleotidebinding protein G(i),
alpha-2 subunit

P08752

Guanine nucleotidebinding protein
G(I)/G(S)/G(T) subunit
beta-1*

P62874

X

C150VLKISDRTPSALAILENANVLAR

X

X
X

X
X
X

X

X

X

X

X

X

X

X

LIVPFC41GHIK

X

LGLKIC47GFLQR

X

X

QSSKNLLSC78ENSDQGAR

X

X

IIKPC112NHVLSLSFPIR

X

X

LVLC99EVFK

X

AC183LYAGVK

X

X

C269IEEAIDKLSK#

X

X

RPSANC346DPYAVTEAIVR#

X

X

IVSNASC150TTNC154LAPLAK#

X

X

VPTPNVSVVDLTC245R

X

X

C270KDVLTGQEFDVR

X

X

C285VINASGPFTDSVR

X

X

FGC319RDPVR

X

X

QLLNC581LHIITLYNR

X

X

EIYTHFTC326ATDTK

X

KAC25ADATLSQITNNIDPVGR#

X

X

ELAGHTGYLSC148C149R#

X

X

LFVSGAC204DASAK#

X

X

ADQELMTYSHDNIIC271GITSVSFSK

X

X

X

X

X

X

FIC
Q61699

X

KC73IGGVIFFHETLYQKDDNGVPFVR

659

Heat shock protein 105
kDa

X

X

YASIC178QQNGIVPIVEPEILPDGDHDL
KR
C202QYVTEKVLAAVYK
QLLLTADDRVNPC73IGGVILFHETLYE
K
C202QYVTEKVLAAVYK

X

X

ALANSLAC339QGK

ALANSLAC339QGK
Galectin-related protein A

X

EQEHEK

VKELNNVC797EPVVTQPKPK

83

X

X

ATDC684VGHDVATLLR

X

X

KLPVGFTFSFPC214R

X

X

C84AADLGLKR

X

LRGGGGNVTLGEC1706SEGK

X

C1940ENLSTPTTLKK

X

P00493

DLNHVC206VISETGK

X

Inositol monophosphatase

O55023

LC183SIPIHGIR

X

X

Inositol-3-phosphate
synthase 1

Q9JHU9

SSVVDDMVHSNHVLYAPGERPDHC38

X

X

Hexokinase-1*

P17710

Histidine triad nucleotidebinding protein 1

P70349

Huntingtin

P42859

Hypoxanthine-guanine
phosphoribosyltransferase

Isocitrate dehydrogenase
[NAD] subunit alpha,
mitocondrial*
Isocitrate dehydrogenase
[NAD] subunit gamma,
mitochondrial
Isoform 11 of Myelin basic
protein
Isoform M1 of Pyruvate
kinase isozymes M1/M2

Q9D6R2

P70404
P0437011
P52480

L-asparaginase

Q8C0M9

LIM and SH3 domain
protein 1

Q61792

L-lactate dehydrogenase
A chain

P06151

L-lactate dehydrogenase
B chain
Long-chain-fatty-acid-CoA ligase 6
Malate dehydrogenase,
cytoplasmic*
Malate dehydrogenase,
mitochondrial
Microtubule-associated
protein 1A*
Microtubule-associated
protein 1B

P16125
Q91WC3
P14152
P08249
Q9QYR6

P14873

X

0VVIK

KTFDLYANVRPC49VSIEGYK

X

DLGGNAKC351SDFTEEIC359RR#

X

TSLDLYANVIHC148K

X

X

X

NIANPTATLLASC333MMLDHLK

X

X

X

SRPGLC79HMYKDSHTR

X

NTGIIC49TIGPASR

X

AGKPVIC326ATQMLESMIK

X

C423LAAALIVLTESGRSAHQVAR

X

C114IANPVKLAR

X

X

TPHC132FLTGHGAEK

X

X

KPYC53NAHYPK

X

X

IVSSKDYC84VTANSK

X

X

VIGSGC163NLDSAR

X

X

HRVIGSGC164NLDSAR

X

X

VIQSVVYC336HGGR

X

X

VIVVGNPANTNC137LTASK#

X

SAPSIPKENFSC154LTR#

X

X

X

VNVPVIGGHAGKTIIPLISQC212TPK

X

X

X

ETEC285TYFSTPLLLGKK

X

SIEEAC160LTLQHLNR

X

X

SAPC2165GSLAFSGDR#

X

X

SALRDAYC1224SEEKELK

X

X

TIKSPC1913DSGYSYETIEK

X

84

X

X

Microtubule-associated
protein 2
Microtubule-associated
protein RP/EB family
member 3
Microtubule-associated
protein tau

YTRPTHLSC1506VK

X

KIDLSHVTSKC1709GSLK

X

Q6PER3

LSNVAPPC182ILRK

X

P10637

C614GSLGNIHHKPGGGQVEVK

X

X

QVC

X

X
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LC SGVLGTVVHGK

X

X

X

GVNEDTYSGFLDC271ARK

X

TTIC109GKGLSATVTGGQK

X

X

X

TSASIGSLC201ADAR#

X

X

X

C164YTQNIDTLER

X

IIAC79DGGGGALGHPK

X

X

TGTC104GYCGLQFKQHHH

X

X

Q99K48

FAC147HSASLTVR

X

X

X

X

X

X

P17742

IIPGFMC62QGGDFTR
HTGPGILSMANAGPNTNGSQFFIC115T
AK
KITISDC161GQL#

X

X

P99029

KGVLFGVPGAFTPGC96SK

X

Q8BGT8

KDPSC321KTC324NISVGR

X

IQSC374YRGEGK

X

GYEC742LFHIPGSPAR

X

X

X

C1011LTPPGHTPGSAPIVININR

X

X

X

P20357

Mitochondrial carrier
homolog 2

Q791V5

Mitochondrial glutamate
carrier 1

Q9D6M3

Myelin proteolipid protein*

P60202

NAD-dependent protein
deacetylase sirtuin-2
NADH dehydrogenase
[ubiquinone] iron-sulfur
protein 6, mitochondrial
Non-POU domaincontaining octamerbinding protein
Peptidyl-prolyl cis-trans
isomerase A*
Peroxiredoxin-5,
mitochondrial*
Phytanoyl-CoA
hydroxylase-interactinglike protein
Plexin-A1

Profilin-1

Q8VDQ8
P52503

P70206

P62962

49QLPGLFC56YAQHIASIDGRR

X

X

X
X

X
X

C128YEMASHLR

X

X

VTVAGLAGKDPVQC46SR

X

X

KGLIAAIC106AGPTALLAHEVGFGC121K

X

X

AYHLAC161KEER

X

X

C132DTC135MMNVHKR

X

X

C143VMNVPSLC151GTDHTERR

X

X

X

Protein DJ-1

Q99LX0

Protein kinase C and
casein kinase substrate in
neurons protein 1

Q61644

Protein kinase C beta
type*

P68404

Protein phosphatase 1
regulatory subunit 1B

Q60829

RPNPC72AYTPPSLK

Putative uncharacterized
protein

Q3ULN6

SVSC218LKPVPIVGTK

Pyridoxal kinase

Q8K183

C273AKAEAGEGQKPSPAQLELR
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X

X

X

X

Pyruvate dehydrogenase
E1 component subunit
alpha, somatic form,
mitochondrial*
Pyruvate dehydrogenase
E1 component subunit
beta, mitochondrial

P35486

Q9D051

Pyruvate kinase isozymes
M1/M2

P52480

Rab GDP dissociation
inhibitor alpha

P50396

Rab GDP dissociation
inhibitor beta
Ras-related C3 botulinum
toxin substrate 1
Ras-related protein Rab14

Sarcoplasmic/endoplasmi
c reticulum calcium
ATPase 2

Secernin-1
Septin-5
Serum albumin

Q61598

X

X

X

EATKFAAAYC273R

X

X

X

QGTHITVVAHSRPVGHC249LEAAAVL
SK

X

NTGIIC49TIGPASR

X

X

X

AGKPVIC326ATQMLESMIK

X

X

IIC302ILSHPIK

X

X

X
X

335

X

X

VGQVIRVIC302ILSHPIK

X

X

KSDIYVC335MISFAHNVAAQGK

X

X

X

KSDIYVC
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MISFAHNVAAQGK

X

X

X

AVLC178PPPVKK

X

X

X

SC26LLHQFTEK

X

X

FMADC40PHTIGVEFGTR

X

X

SMSVYC498TPNKPSR

X

GAPEGVIDRC524THIR

X

C560LALATHDNPLKR

X

NYLEQPGKEC998VQPATK

X

X

X

C186IC188NHLSLATKLDEEHPELR

X

X

X

SSPC290IHYFTGTPDPSR

X

X

X

Q9Z2Q6

DVTC300DVHYENYR

X

X

X

P07724

LQTC302C303DKPLLKK

X

TSLRPQTFYDGSHC130SAR

X

C163HSKGTIVTIEGPR

X

TVTVNDC607EAKVKGDGTISAITEK

X

C518SSILLHGK

X

X

X

AAVPDAVGKC606R

X

P63001
Q91V41

O55143

Q9CZC8

S-methyl-5'-thioadenosine
phosphorylase

Q9CQ65

Sodium- and chloridedependent GABA
transporter 3

P31650

Sodium/potassiumtransporting ATPase
subunit alpha-1

C41DLHRLEEGPPVTTVLTR

Q8VDN2

HHC

PNTPIILVGTK

663

DAKAC VVHGSDLK
LIIVEGC705QRQGAIVAVTGDGVNDSP
ALKK

86

X
X

Sodium/potassiumtransporting ATPase
subunit alpha-2*

IISSHGC209KVDNSSLTGESEPQTR

X

X

ILDRC515STILVQGK

X

X

553

Q6PIE5

VLGFC

603

AAVPDAVGKC

X

R

X

YNTDC49VQGLTHSKAQEILAR#

X

X

X

X

X

X

X

X

IISAHGC
221

SPDC

KVDNSSLTGESEPQTR#

THDNPLETR
449

Sodium/potassiumtransporting ATPase
subunit beta-1*
Succinate dehydrogenase
[ubiquinone] flavoprotein
subunit, mitochondrial
Superoxide dismutase
[Cu-Zn]*
Synaptophysin*
Syntaxin-binding protein 1
TAR DNA-binding protein
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Transketolase

Tubulin alpha-1A chain*

Tubulin alpha-1B chain

DVAGDASESALLKC

Tubulin beta-2A chain

Tubulin beta-2B chain*

IELSSGSVK#

X

ILDRC508ATILLQGK#

X

VLGFC546HYYLPEEQFPK

X

AAVPDAVGKC596R

X

AC653VIHGTDLK#

X

LIIVEGC695QRQGAIVAVTGDGVNDSP
ALKK#

X

YNPNVLPVQC214TGKR#

X

TYFSC266TSAHTSTGDGTAMVTR

X

AC467ALSIAESC475RPGDKVPSIK

X

X

P08228

AVC7VLKGDGPVQGTIHFEQK#

X

X

Q62277

LHQVYFDAPSC87VK#

X

AAHVFFTDSC110PDALFNELVK

X

X

LAEQIATLC180ATLKEYPAVR

X

X

Q6PIC6

P14094

Q8K2B3

O08599
E9Q830

YRNPVSQC50MR

P40142

DRTVPFC386STFAAFFTR
AYHEQLSVAEITNAC295FEPANQMVK
#
YMAC315C316LLYRGDVVPK

X

TIQFVDWC347PTGFK

X

P68369

P05213

305

C

305

Tubulin alpha-4A chain*

X

LIIVEGC702QRQGAIVAVTGDGVNDSP
ALKK#

201

Sodium/potassiumtransporting ATPase
subunit alpha-3*

X

QLNLPSGKFPR

P68368

Q7TMM9

Q9CWF2

C

X

X

X

315

DPRHGKYMAC

315

DPRHGKYMAC

X

X
X

X

316

LLYR

X

X

316

LLYR

X

X

C
C

X

SIQFVDWC347PTGFK#

X

MREIVHIQAGQC12GNQIGAK

X

NMMAAC303DPRHGRYLTVAAIFR

X

TAVC354DIPPRGLK

X

EIVHIQAGQC12GNQIGAK

X

X

NMMAAC303DPRHGR

X

X
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X

Tubulin beta-2C chain*

Tubulin beta-3 chain
Tubulin beta-4 chain*
Tubulin beta-5 chain

P68372

Q9ERD7
Q9D6F9
P99024

Tubulin polymerizationpromoting protein

Q7TQD2

Ubiquitin carboxyl-terminal
hydrolase isozyme L1*

Q9R0P9

Ubiquitin thioesterase
OTUB1

Q7TQI3

Ubiquitin-conjugating
enzyme E2 O

Ubiquitin-like modifieractivating enzyme 1
Uncharacterized protein

Vesicle-fusing ATPase*

Voltage-dependent anionselective channel protein
3*

Q6ZPJ3

Q02053

E9QM90

P46460

Q60931

V-type proton ATPase
subunit B, brain isoform

P62814

Zinc transporter ZIP6

Q8C145

EIVHIQAGQC12GNQIGAK#
TLKLTTPTYGDLNHLVSATMSGVTTC2
39LR
NMMAAC303DPRHGRYLTVAAVFR

X

TAVC354DIPPRGLK

X

12GNQIGAK

X
X
X

MREIVHIQAGQC

X

VAVC354DIPPRGLK

X

EIVHLQAGQC12GNQIGAK#

X

MREIVHIQAGQC12GNQIGAK

X

NMMAAC303DPRHGRYLTVAAVFR

X

TAVC354DIPPRGLK

X

79KDC82HVIDGK

LC

X

NEAIQAAHDSVAQEGQC152R

X

FSAVALC220K

X

X

TRPDGNC91FYR

X

X

LGC336FDHAQR

X

C348LYVFPAKVEPAK

X

YSRPAQLHIGFQALHQFC340ALHNQP
PRPR
C588VYYRKPLLESGTLGTK

X

LSPAFHQALLSFC497R

X

C526LPHIVPNVLLAK

X

X

X

X

X

C11PTDELSLSNC21AVVNEKDFQSGQ
HVMVR
THPSVVPGC59IAFSLPQRK

X

GILLYGPPGC264GK

X

YKVC65NYGLTFTQK#

X

YKLDC229RTSLSAK

X

112EFTGDILR

X

X

X
X
X
X

KTSC

X

GQKIPIFSAAGLPHNEIAAQIC207R

X

KAFC153PDLDSDNSGKNPR

X

X

AC312LIHTASEK

X

X

X denotes identification of peptide in a given genotype. The peptides corresponding to wild-type
mice have been identified in at least three biological replicates.
* denotes proteins identified in previously published studies as endogenously S-nitrosylated in
mouse brain
# denotes peptides identified in previously published studies as endogenously S-nitrosylated in
mouse brain
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3.4 Materials and Methods
Chemicals and Reagents
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO), unless
otherwise indicated. Rabbit polyclonal antibody against GLT1 was a gift from Dr.
Jeffrey Rothstein (Johns Hopkins University School of Medicine, Baltimore, MD).
Goat polyclonal antibodies against mAspAT and GDH were purchased from
Abcam (Cambridge, MA).

Mouse monoclonal antibody against GS was

purchased from Millipore (Bedford, MA). L-[3,4-3H] glutamic acid was purchased
from Perkin-Elmer (Waltham, MA).

Affigel-10 was purchased from Bio-Rad

(Hercules, CA). EZLink Sulfo-NHS-Biotin and UltraLink monomeric avidin beads
were purchased from Pierce (Rockford, IL).
Animals
All procedures were performed in strict accordance with the National
Institutes of Health Guide for the Care and Use of Laboratory Animals and were
approved by the Children’s Hospital of Philadelphia Animal Care and Use
Committee.

Male mice between 10-12 weeks old were used for proteomic

studies, enzymatic assays and synaptosomal uptake, while those between 8-10
weeks old were used for

15N

stable isotopic profiling.

Wild-type C57BL/6J

(#000664), Nos1tm1Unc C57BL/6J (nNOS–/–: #002986), and Nos3tm1Unc C57BL/6J
(eNOS-/-: #002684) mice were obtained from Jackson Laboratories (Bar Harbor,
ME).

For experiments except those involving isotopic profiling, mice were

anesthetized by CO2 and perfused through the left ventricle with ice-cold PBS.
Intact organs were collected, immediately frozen in liquid nitrogen, and stored at 80 °C until use.
Identification of Protein S-Nitrosocysteine Sites
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A detailed experimental procedure for the preparation and activation of
columns, as well homogenate preparation for reaction with organic mercury
resin, has been previously published (30). Six biological replicates from each
genotype were analyzed. Each sample had a corresponding UV-pretreated
negative control analyzed under identical conditions. The number of peptides
identified in both untreated and UV-pretreated homogenates was used to
calculate the false identification rate (FIR). The FIR was calculated
independently for each biological replicate and the average value is reported.
Overall, the FIR across the six biological replicates was 5.2 ± 0.7 %, which is
within the range of FIR reported for site specific identification of other posttranslational modifications using enrichment approaches (77-78). Columns were
initially washed with 50 bed volumes of 50 mM Tris-HCl, pH 7.4, containing 0.3 M
NaCl, 0.5% SDS, followed by 50 bed volumes of the same buffer containing
0.05% SDS. Columns were then washed with 50 bed volumes of 50 mM TrisHCl pH 7.4, containing 0.3 M NaCl, 1% Triton X-100, 1M Urea. This was
followed by 50 bed volumes of the same buffer containing 0.1% Triton X-100, 0.1
M urea. Finally, columns were washed with 200 bed volumes of water before
proteins were eluted with 10 mL of 50 mM β-mercaptoethanol in water. Samples
were concentrated and resolved by one-dimensional SDS-PAGE, followed by
either western blot analysis or in-gel trypsinization and subsequent LC-MS/MS
analysis (28-30, 79).
For quantification of S-nitrosylated GLT1, GDH, mAspAT, and GS from
wild-type mouse brain, the same protein capture protocol described above was
followed. The eluted bound proteins, representing the S-nitrosylated fraction, 30
µg of input homogenate (total protein) and different dilutions of recombinant
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standard proteins were resolved by one-dimensional SDS-PAGE and transferred
to Immobilon-FL PVDF membranes (Millipore, Bedford, MA). After probing with
appropriate antibodies, blots were scanned by the Odyssey Infrared Imaging
System (LI-COR, Lincoln, NE).
To identify sites of S-nitrosocysteines, columns were washed with 10 bed
volumes of 0.1 M ammonium bicarbonate after the final wash with water in the
previously described method. Bound proteins were subjected to digestion by the
addition of 1 μg/mL of trypsin gold (Promega, Madison, WI) in one bed volume of
0.1 M ammonium in the dark for 16 hours at room temperature. The resin was
next washed with 40 bed volumes of 1 M ammonium bicarbonate, pH 7.4,
containing 300 mM NaCl, followed by 40 volumes of the same buffer without
NaCl. Columns were then washed with 40 volumes of 0.1 M ammonium
bicarbonate followed by 200 volumes of deionized water. Performic acid was
synthesized by reacting 1% formic acid and 0.5% hydrogen peroxide for at least
60 minutes at room temperature (with rocking) in a glass vial shielded from light.
To elute bound peptides, the resin was incubated with one bed volume of
performic acid in water for 30 minutes at room temperature (28-30). Eluted
peptides were recovered by washing the resin with one bed volume of deionized
water. Eluates were stored at -80 °C overnight followed by lyophilization and resuspension into 300 μL of 0.1% formic acid. Peptide suspensions were
transferred to low retention tubes (Axygen, Union City, CA) and the volume was
reduced to 30 μL by speed vacuum. Twenty μL of peptide suspension was
transferred to an HPLC vial and submitted for LC-MS/MS analysis. The details
for MS/MS analysis have been provided previously (28-30, 79). Post-MS
analysis to generate the S-nitrosocysteine proteomes (Table S1) was performed
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as described previously (28-30). The peptides that are reported for the wild-type
mice had been identified in at least three biological replicates.
Gene Ontology Analysis
Proteins in supplemental table S1 were mapped to UniprotIDs and only
reviewed, non-fragment proteins were retained in the final proteome. A mouse
brain reference brain proteome consisting of 7025 proteins was generated from
the literature (31-34) and our experimental data. For gene ontology (GO)
analysis, the Ratio of Enrichment (R) score was calculated by WebGestalt (35)
as the ratio (O/E) of the observed number (O) of proteins with a specific GO
annotation in the S-nitrosocysteine proteome vs. the number of annotated
proteins expected (E) to be in the S-nitrosocysteine proteome. E is derived from
the number of proteins annotated as part of a specific molecular pathway in the
whole brain proteome normalized to the number of total proteins in the whole
brain protein proteome (and multiplied by the total number of S-nitrosylated
proteins). Significant enrichment was evaluated at an adjusted cutoff of 0.01,
with the top ten enriched pathways considered for further analysis.
Glutamate/Glutamine Metabolism Studies
For isotopic profiling studies, three mice per genotype were analyzed.
Each day samples from one mouse per genotype were prepared and analyzed.
Animals were anesthetized with isoflurane and decapitated. The brain was then
rapidly removed and coronal hippocampal slices (400 μm) cut with a vibratome
(Vibratome 1000 Plus, Vibratome, St. Louis, MO) in an ice-cold artificial
cerebrospinal fluid solution (ACSF) of the following composition: 202 mM
sucrose, 3 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose, 1 mM
MgCl2, 2 mM CaCl2, pH 7.2–7.4 (when saturated with 95% O2-5% CO2). Slices
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were then equilibrated for 2 hours at 34°C in ACSF containing 130 mM NaCl
instead of sucrose. Following equilibration, hippocampal slices were transferred
into cell culture inserts and incubated in a 24-well plate for 45 minutes at 34°C in
1 mL depolarizing artificial cerebrospinal fluid (dACSF) containing the following:
130 mM NaCl, 3 mM KCl, 1.25 mM NaH2PO4, 26 mM NaHCO3, 10 mM glucose,
2 mM CaCl2, 1 mM [2-15N] L-glutamine, and 0.3 mM NH4Cl. Medium was then
collected from each sample and frozen at -80°C, and slices were washed with 2
mL chilled D-PBS. Slices were homogenized in 4% perchloric acid and
subjected to two freeze/thaw cycles, with a subsequent centrifugation step at
10000 x g for 15 minutes. Supernatant was collected from each slice, which
contained the metabolites of interest, and protein pellets were separately
resuspended in 1 M NaOH. Protein content per slice was determined using the
Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). Supernatant from each sample
was neutralized with KOH and used for metabolite determination and
measurement of 15N enrichment by GC-MS (40-41).
Enzymatic Assays
For enzymatic activities three mice per genotype were analyzed. Each
day, three mice (one mouse per genotype) were analyzed. Enzymatic activities
were quantified in triplicates with technical reproducibility greater than 90%.
Following, the average raw values were normalized to those of untreated wildtype homogenate analyzed in the same day.
For glutamine synthetase activity, frozen tissue from mouse brain cortex
were processed as described previously (80) with minor modifications. Briefly,
cortices were homogenized in 5 volumes of 0.1 M imidazole pH 7.2 using an
Ultra-Turax homogenizer. Homogenates were centrifuged at 10000 x g for 10
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min at 4°C, and the clarified supernatant used for assessing glutamine
synthetase activity (with protein concentration determined using the Bio-Rad
Protein Assay). For UV light exposure to eliminate NO from S-nitrosocysteine,
part of each sample from wild-type mice was trans-illuminated by UV light while
on ice for 3 minutes. Activity was determined in triplicate using 90 μg of clarified
homogenate in a total volume of 70 μL of reaction buffer (1 mM L-glutamate, 20
mM ATP, 40 mM MgCl2, 0.1 M hydroxylamine, 0.1 M imidazole pH 7.2), after
incubation for 20 minutes at 37°C. The reaction was stopped by the addition of
190 μL of 0.37 M FeCl3 in 0.67 M HCl/0.2 M TCA, and samples were incubated
on ice for 5 minutes. Sample mixtures were then centrifuged at 4 °C for 5
minutes at 10000 x g, and the absorbance of the resulting supernatant was
measured at 535 nm and compared to a standard curve of authentic Lglutamylhydroxamate. GS activity was expressed as nmol of Lglutamylhydroxamate per mg of protein per hour. Enzymatic specificity of the
assay was determined using 0.5 mM L-methionine sulfoximine (MSO) as a
selective GS inhibitor.
For glutamate dehydrogenase activity, frozen forebrain was processed
using the Mitochondrial Isolation Kit from Sigma-Aldrich. The final mitochondrial
pellet was resuspended in mitochondrial resuspension buffer containing 0.32 M
sucrose, 10 mM Tris-HCI pH 7.4, 0.5 mM EDTA, 0.1% Triton X-100, and protein
concentration was determined using the Bio-Rad Protein Assay. Glutamate
dehydrogenase activity was determined as described previously (81). Briefly,
activity in the direction of oxidative deamination was assayed in a UV/Vis
spectrophotometer (HP 8452A, GMI-Inc., Ramsey, MN) at 25°C using 15 μg of
mitochondrial protein in a final volume of 200 μL of assay buffer (150 mM KCl,
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0.1 mM rotenone, 20 mM Tris-HCl pH 7.6, 2 mM EGTA, 1 mM NAD+, 2.5 mM
glutamate). The velocity of each reaction was calculated from the linear portion
of the change in NADH absorbance measured at 340 nm. Enzymatic specificity
of the assay was determined using 20 μM GTP as a selective GDH inhibitor.
For mitochondrial aspartate aminotransferase activity, mitochondrial
extracts were prepared exactly as described for GDH activity. Enzymatic activity
was determined as described previously (82), with minor modifications. Briefly,
activity in the direction of α-ketoglutarate production was assayed
spectrophotometrically using 15 μg of mitochondrial protein in a final volume of
200 μL of assay buffer (0.02% BSA, 0.1 mM rotenone, 100 mM ADP, 30 mM
NH4Cl, 120 μM NADPH, 5 mM Glu, 2.5 mM oxaloacetic acid, and 15 μg of
purified bovine GDH). The decrease in NADPH absorbance at 340 nm at room
temperature was followed over 15 minutes and used to calculate the velocity of
mAspAT activity. Enzymatic specificity of the assay was determined using 1 mM
aminooxyacetic acid (AOAA) as a selective mAspAT inhibitor.
For synaptosomal glutamate uptake, crude synaptosomes were prepared
from forebrain as previously described (49, 83) with minor modifications. Briefly,
animals between 10-12 weeks of age were anesthetized with isoflurane and
decapitated. Forebrains from wild-type, nNOS -/-, and eNOS -/- mice was
dissected and homogenized on ice in 20 volumes of sucrose buffer (0.32 M
sucrose, 0.1 mM DTPA pH 5.3), while protected from light. Homogenates were
centrifuged at 800 x g for 10 minutes at 4°C, and the supernatants were isolated
for further processing. Samples from wild-type mice homogenized in sucrose
buffer without DTPA were also pre-treated at 4°C with 50 μM CuSO4/500 μM
ascorbate for 30 minutes in the dark to remove NO from S-nitrosocysteine. All
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samples were then centrifuged at 20,000 x g for 20 minutes at 4 °C, and the
pellets were resuspended in 0.32 M sucrose, 0.1 mM DTPA (pH 5.3). Samples
were then centrifuged a final time at 4 °C at 20,000 x g for 20 minutes, with
pellets finally resuspended in 0.32 M sucrose (pH 5.3). Sodium-dependent
transport of L-3[H]glutamate was then measured as described previously (49, 83)
in the presence or absence of 0.3 mM dihydrokainate (DHK) in order to
determine DHK-sensitive glutamate uptake (as a measure of excitatory amino
acid transporter 2 activity).
Plasmid Constructs
Plasmid expressing rat excitatory amino acid transporter 2 was obtained
from Dr. Baruch Kanner (Hebrew University, Hadassah Medical School,
Jerusalem, Israel). The Quikchange Lightning Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA) was used to introduce single amino acid
mutations in the transporter as follows. Cysteine-to-serine mutations were
introduced using the forward/reverse primer pairs: for Cys373, 5’TTGCCTGTCACCTTCCGTAGCTTGGAAGATAATC-3’ and
5’-GATTATCTTCCAAGCTACGGAAGGTGACAGGCAA-3; and for Cys562,
5’- ATGGAAAGTCAGCTGACAGCAGTGTTGAGGAAGAA-3’ and 5’TTCTTCCTCAACACTGCTGTCAGCTGACTTTCCAT-3’, resulting in the
C373S/C562S construct. All plasmid constructs were verified by sequencing
prior to use.
Cell Culture, Transfection, and CysNO Treatment
HEK-293T cells were grown in Dulbecco's Modified Eagle Medium
(DMEM) with Glutamax from Life Technologies (Carlsbad, CA) containing 10%
fetal bovine serum (FBS), 100 U/mL penicillin, and 100 ng/mL streptomycin, at
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37°C in air with 5% CO2. Cells were plated at a density of 1.25 × 105 cells/cm2
and cultured under normal conditions for 24 hours. Cells were transfected with
wild-type excitatory amino acid transporter 2 (WT GLT1) or the double mutant
C373S/C562S transporter using the Clontech CalPhos transfection kit (Clontech,
Mountain View, CA) according to manufacturer’s protocol. At eighteen hours
post-transfection the growth medium was replaced with serum-free DMEM and
equilibrated for 2 hours at 37°C. Afterwards, freshly prepared S-nitrosocysteine
(CysNO) or cysteine (Cys) was added up to a final concentration of 0.4 mM, and
cells were incubated for 2 hours. Cells were extensively washed with PBS, and
used for measuring glutamate uptake as described previously (84). Lysates
were assayed for protein concentration using the Lowry assay and used to
determine excitatory amino acid transporter 2-mediated glutamate uptake initial
velocity, described in nmol/mg/min. For cell surface biotinylation studies, cells
were processed as described previously (84). Briefly, after Cys or CysNO
treatment cell monolayers were washed twice with ice-cold DPBS (pH 7.4)
containing 0.1 mM CaCl2 and 1.0 mM MgCl2. Cells were then incubated in 2 mL
of biotinylation solution (1 mg/mL EZLink Sulfo-NHS-Biotin in DPBS with 0.1 mM
CaCl2 and 1.0 mM MgCl2) for 30 minutes at 4°C. The biotinylation solution was
then aspirated, and excess biotin was quenched by incubating cells with DPBS
containing 100 mM glycine for 30 minutes at 4°C. Cells were then lysed in 1 mL
RIPA buffer with protease inhibitors (1 μg/mL leupeptin, 250 μM
phenylmethanesulfonyl fluoride, 1 μg/mL aprotinin, and 1 mM iodoacetamide).
Lysates were then centrifuged to remove cellular debris, and biotinylated proteins
were batch extracted from the supernatant using UltraLink monomeric avidin
beads. LDS sample buffer was added to fractions containing total cell lysate,
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biotinylated proteins (cell surface proteins), and nonbiotinylated proteins
(intracellular proteins). Each fraction was diluted and loaded such that the sum
of immunoreactivity in the nonbiotinylated and biotinylated fractions should equal
the immunoreactivity found in the lysate, assuming avidin extraction of
biotinylated proteins is 100%. For reversibility studies, uptake was studied in
cells at 0, 60, 120 and 240 minutes after the removal of CysNO. Additionally,
lysates from each treatment condition were processed in parallel as previously
described (28-30) for S-nitrosoprotein enrichment and subsequent Western blot
detection of S-nitrosylated excitatory amino acid transporter 2.
Molecular Modeling of the Effects of S-nitrosylation
The

2.4Å

resolution

crystal

structure

of

mitochondrial

aspartate

aminotransferase was taken from PDB 3PD6 (53). The 2.7Å resolution crystal
structure of human glutamate dehydrogenase was taken from PDB 1L1F (54).
The 2.6Å resolution crystal structure of human glutamine synthetase was taken
from PDB 2QC8 (55). Structures of mAspAT with S-nitrosyl modified cysteine
(SNC) at positions 106 and 295, GDH with SNC at position 59 (equivalent to
position 112 in the mouse sequence) and GS with SNC at positions 99, 183, 269
and 346 were built using VMD and a custom SNC residue template (56).
Electrostatic potentials from the cysteine or SNC residues were calculated using
the finite difference Poisson-Boltzmann method as described previously (57-58).
The solvent was assigned a dielectric of 78.6 and an ionic strength of 145 mM.
The protein was assigned a dielectric of 2. Partial atomic charges for the
unmodified cysteine residue were taken from the CHARMM27 molecular
mechanics forcefield (59). Atomic charges for SNC were obtained from
electronegativity neutralization using the program QEQUIL (60), giving +0.35
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(CβH2), -0.17 (Sγ), +0.06 (Nδ), and -0.24 (Oε), in atomic charge units. Structures
and potentials were visualized using PyMol (61).
Statistical analysis
Data were analyzed with GraphPad Prism 5.0d software. All normally
distributed data were displayed as means ± SE. Groups were analyzed by oneor two-way analysis of variance (ANOVA), with appropriate post-hoc tests.
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CHAPTER 4

CONCLUSIONS AND FUTURE DIRECTIONS
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4.1 Summary
S-nitrosylation has gained prominence in recent years as a major
mechanism for the˙NO-dependent regulation of structure and function for
individual proteins. However, much is still unknown regarding how this
posttranslational modification may coordinate diverse biological processes in
response to specific stimuli. For this thesis, we uncovered multiple protein
targets of physiological S-nitrosylation in the mouse that rely on either nNOSderived or eNOS-derived ˙NO for detection, and demonstrate a role for nNOS in
the regulation of the glutamate/glutamine cycle during excitatory
neurotransmission. In the process, we took advantage of the plethora of data
available from our proteomic studies to generate hypotheses that were tested
using a variety of metabolomic, biochemical, and molecular biology approaches.

4.2 The necessity of mass spectrometry-based proteomic approaches
in comprehensively studying biological change
Proteomic methodologies represent a powerful addition to other global
interrogations of cellular response, including genomic and transcriptomic
screens. In particular, their ability to identify proteins from complex mixtures
(when coupled to upstream chromatographic separation techniques) makes MSbased proteomics a toolset of choice for many cell signaling studies. The value
of this work can be further enhanced with the use of various complementary
approaches, including stable isotopic labeling-based protein quantification and/or
selective enrichment techniques available for specific posttranslational
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modifications. Despite these advances, the depth of proteomic analysis is still
limited in comparison to published genomic screens: in humans, only ~84% of
protein-coding genes identified in the genome have been matched to proteins
detected by MS1. This gap will narrow in the coming years, however, with
refinements in both genome annotation and proteomic methodologies.
Regardless of this caveat, MS-based proteome analysis still represents the most
useful route for investigating global changes in protein homeostasis that
accompany given physiological stimuli, and can generate the preliminary
information needed for more targeted hypotheses of biological function.
Application of our protocol for S-nitrosoprotein enrichment and subsequent
LC-MS/MS analysis to the wild-type mouse brain yielded the most
comprehensive physiological S-nitrosoproteome currently available for this
organ, with an improvement of 225 additional sites and 92 additional protein
targets over previous reports. Comparison of this dataset to those we obtained
from nNOS-/- and eNOS-/- brain allowed us to make hypotheses about the
contributions of nNOS-derived ˙NO to normal CNS function, and afforded the
opportunity to explore them in more detail using traditional biochemistry and
molecular biology approaches. In doing so, we provided evidence for Snitrosylation as a global regulator of synaptic transmission through its regulation
of glutamate availability, and offered a prime example for the importance of MSbased proteomics in leading to focused mechanistic studies.

115

4.3 Systemic regulation of brain physiology by S-nitrosylation
Our work uncovered 136 protein targets of S-nitrosylation in the wild-type
mouse brain. Subsequent gene ontology analysis revealed 6 of these proteins to
be directly involved in glutamate/GABA metabolism and the glutamate/glutamine
cycle, with 4 proteins further scrutinized for S-nitrosylation-dependent regulation
of glutamate oxidation/transport/recycling to glutamine. Intriguingly, we also
found an additional 29 proteins that participate in various stages of cellular
metabolism, including glycolysis (Figure 1), the tricarboxylic acid (TCA) cycle
(Figure 2), and oxidative phosphorylation (Table 1). Each of these processes
indirectly contributes to steady-state levels of glutamate, principally through
regulation of the synthesis or consumption of its 5-carbon backbone. Curiously,
some proteins from each pathway were found to be S-nitrosylated in WT, eNOS-/, and nNOS-/- brain, suggesting one or both of the following possibilities: 1)
redundancy between eNOS- and nNOS-derived ˙NO in modifying said protein(s),
or 2) ˙NO from another source common to all genotypes (such as iNOS) was
utilized instead. Conversely, a few proteins from each pathway were only
observed in the WT brain, suggesting that for them both eNOS- and nNOSderived ˙NO may be necessary to modify enough protein to be detected by our
method. Regardless, given the significant convergence between S-nitrosylation,
metabolism, and excitatory neurotransmission, a role for eNOS- and/or nNOSderived ˙NO in coordinating the latter two processes is a strong possibility.
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Figure 4.1: S-Nitrosylation in Glycolysis. Multiple enzymes involved in the synthesis and metabolism of glycolytic
substrates are modified by cysteine S-nitrosylation. 1) Enzymes denoted in blue had detectable S-nitrosocysteine
residues in wild-type and nNOS-/- brain, but not eNOS-/- (eNOS-dependent). 2) Those denoted in red had detectable Snitrosocysteine residues in wild-type and eNOS-/- brain, but not nNOS-/- (nNOS-dependent). 3) Those denoted in green
had detectable S-nitrosocysteines in wild-type, nNOS-/-, and eNOS-/- brain (suggesting redundancy between nNOS and
eNOS, or possibly iNOS dependence). 4) Those denoted in yellow were only found to be modified in wild-type brain, not
nNOS-/- or eNOS-/- (require both isoforms). 5) Those denoted in black were not detectable as S-nitrosylated in any
genotype.
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Figure 4.2: S-Nitrosylation in the Tricarboxylic Acid Cycle. Several enzymes in the TCA cycle are modified by
cysteine S-nitrosylation. 1) Enzymes denoted in blue had detectable S-nitrosocysteine residues in wild-type and nNOS-/brain, but not eNOS-/- (eNOS-dependent). 2) Those denoted in red had detectable S-nitrosocysteine residues in wild-type
and eNOS-/- brain, but not nNOS-/- (nNOS-dependent). 3) Those denoted in green had detectable S-nitrosocysteines in
wild-type, nNOS-/-, and eNOS-/- brain. 4) Those denoted in yellow were only found to be modified in wild-type brain, not
nNOS-/- or eNOS-/- (suggesting redundancy between nNOS and eNOS, or possibly iNOS-dependent ). 5) Those denoted
in black were not detectable as S-nitrosylated in any genotype.
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Protein Name
NADH
dehydrogenase
[ubiquinone] ironsulfur protein 6,
mitocondrial
(Complex I)
Succinate
dehydrogenase
[ubiquinone]
flavoprotein
subunit,
mitochondrial
(Complex II)
Electron transfer
flavoproteinubiquinone
oxidoreductase,
mitocondrial
(Complex II)
Cytochrome b-c1
complex subunit 6,
mitochondrial*
(Complex III)
Cytochrome c1,
heme protein,
mitochondrial
(Complex III)
Cytochrome c
oxidase subunit 5B,
mitochondrial*
(Complex IV)
ADP/ATP
translocase 1
ATP synthase
subunit alpha,
mitochondrial
ATP synthase
subunit gamma,
mitochondrial

Uniprot ID

WT

eNOS-/-

nNOS-/-

P52503

X

X

X

Q8K2B3

X

X

X

Q921G7

X

P99028

X

Q9D0M3

X

P19536

X

P48962

X

Q03265

X

Q91VR2

X

X

X

X

X

Table 4.1: S-Nitrosylated Proteins in Oxidative Phosphorylation. At least one protein in each of the 4 major
complexes of the electron transport chain contains S-nitrosocysteines that were detected in the wild-type mouse brain. Snitrosoprotein targets are denoted above, along with the genotypes in which they were observed.
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Many of the emergent concepts of ˙NO-dependent metabolic control found
in our work are supported by previous reports. eNOS-derived ˙NO from
endothelial cells has been shown to increase aerobic glycolysis and lactate
production in astrocytes in co-cultures via HIF-1α-mediated transcription2, a
result reinforced by earlier studies documenting elevated astrocytic glycolysis
after treatment with ˙NO donors3-4. Such effects on glucose metabolism may at
least in part be explained by our proteomic analyses, which found eNOSdependent S-nitrosylation of enzymes responsible for the first steps of glucose
phosphorylation (Figure 1). Our identification of nNOS-dependent S-nitrosylation
of inositol-3-phosphate synthase 1 and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in the brain (Figure 1) also suggests an a role for
nNOS-derived ˙NO in the regulation of glycolysis, with nNOS-dependent GAPDH
S-nitrosylation validated by previous studies5-6. Additionally, NMDA receptordependent activation of nNOS has been associated with inhibition of the TCA
cycle in rat striatum7, an observation consistent with both the increased
glutamate oxidation8 and reduced numbers of S-nitrosocysteine residues in TCA
cycle enzymes we identified in nNOS-/- brain (Figure 2). However, though
differences exist between eNOS-derived and nNOS-derived S-nitrosylation in
their respective protein targets, it may very be that both NOS isoforms are used
to coordinate the large-scale shifts in metabolism necessary to support changes
in synaptic plasticity.
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Taking into account the intimate links that we and others have established
between the glutamate/glutamine cycle8, glucose metabolism9, and synaptic
plasticity10, one can appreciate the metabolic support necessary for long-term
changes in excitatory neurotransmission. Based on the data presented herein,
nitric oxide may act as a mediator between these biological processes via
specific NOS isoform-dependent S-nitrosylation of key effector proteins in each
cellular pathway. Moreover, in lieu of the regulatory contributions of this
posttranslational modification to glutamate availability, the developmental
significance of nNOS-derived ˙NO11-16 can be better understood.

4.4 Implications and future directions
The results of this study, as well as those of other groups17-21, reinforce
the vital influence of nNOS-derived ˙NO in glutamatergic transmission. Our data
suggests that at least part of this ˙NO-dependent regulation is achieved through
the S-nitrosylation of key proteins involved in glutamate transport, oxidation, and
recycling to glutamine. Still, the relevance of this phenomenon to multiple
aspects of neurobiology, including plasticity, development and
neurodegeneration, is yet to be explored.
4.4.1 Stoichiometry
Our findings revealed that roughly 8-25% of all molecules for each of the
four proteins studied (GLT1, GDH, mAspAT, and GS) were modified by Snitrosylation8, values that are in line with those described for other enzymes22. At
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first glance, these numbers appear incongruous with the changes in protein
activity observed between wild-type and nNOS-/- brain (or after S-nitrosothiol
elimination in wild-type extracts): GLT1, GDH, and mAspAT function was
inhibited by 20-80% when S-nitrosylated in vivo, while GS activity was decreased
by 40% upon S-nitrosothiol elimination8. However, each of the four proteins in
question assemble into multimeric complexes: GLT1 as a trimer23 , GDH as a
hexamer24 , mAspAT as a tetramer25 , and GS as a decamer26 . Given this
information, S-nitrosylation of one or more monomers in each multimer may act
in a dominant-negative (for GLT1, GDH, and mAspAT) or dominant-positive
manner (for GS) in regulating protein function. Such a concept is further
reinforced by our molecular modeling studies of the modification for GDH,
mAspAT, and GS, which revealed that S-nitrosylation of the cysteines identified
in vivo generates a repulsive electrostatic wedge between subunits that could
plausibly drive allosteric regulation of protein function8.
Stoichiometric studies of posttranslational modifications traditionally rely
on the substitution of modified amino acids in proteins with “mimetics,” such as
aspartate/glutamate (for phosphoserine/phosphothreonine27) or glutamine (for
acetyllysine28). On the other hand, such an approach has not been as robustly
validated for protein S-nitrosocysteine residues: several groups have attempted
to do so through replacement of cysteine residues with alanine29 or tryptophan30
in order to recapitulate the effects of S-nitrosylation, with mixed results. Still,
coexpression of “nitrosomimetic” Cys-to-Ala/Cys-to-Trp mutant proteins with non122

nitrosylatable Cys-to-Ser mutants (which, at least for GLT1, have been shown to
have comparable basal activity to the wild-type protein8) may be worth
investigating in order to ask how the stoichiometry of S-nitrosylation relates to its
effects on protein function in vitro and in vivo.
4.4.2 Spatiotemporal Regulation of Nitric Oxide and S-Nitrosylation in
Synaptic Plasticity
Most of our analyses of S-nitrosylation and its effects on protein function
were performed in samples from 8-12 week old mice of WT, nNOS-/-, and eNOS-/genotypes. In doing so, we measured enzyme and transporter activity in the
presence of steady-state levels of S-nitrosylation established during CNS
development in these animals. Because of this, it is natural to wonder about the
on/off kinetics of the modification and its effects on glutamate/glutamine
metabolism, particularly within time scales used for monitoring acute changes in
synaptic function (milliseconds to seconds) and synaptic plasticity (minutes to
hours). Unfortunately, it is not currently possible to detect changes in protein Snitrosylation within the short periods of time used for measuring acute changes in
synaptic function. Despite this limitation, however, conclusions can still be made
about the roles of ˙NO and S-nitrosylation in supporting synaptic plasticity.
Several long-term changes in plasticity (i.e. in long-term potentiation)
occur minutes to hours after the initial paired presynaptic/postsynaptic tetanic
stimuli31. ˙NO-dependent signaling is thought to augment this process, rather
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than acting alone as a retrograde neurotransmitter32. Moreover, within a similar
period of time following stimulation, ˙NO diffuses over a radius of 100-200 μm
from its postsynaptic source19,33, allowing it to reach multiple cellular
compartments of the tripartite synapse. Given that our analyses8 of
glutamine/glutamate utilization (via metabolomics) and S-nitrosylation reversibility
(in vitro) was performed within similarly relevant time periods (minutes to hours
following chemical stimulation or S-nitrosocysteine treatment), the data we
obtained points toward S-nitrosylation as more of a long-term regulator of
synaptic plasticity rather than a short-term affector of synaptic function. This
finding is reinforced by previous reports from other groups, which have
documented differences in S-nitrosylation and function of specific proteins within
a period of minutes to hours following stimulation34-36.
4.4.3 Therapeutic Implications in Neurological Disorders
Neuronal nitric oxide participates in several processes during CNS
maturation, including neurogenesis37-41, excitatory synapse development42-43,
neuronal migration44 and differentiation37. In light of the reciprocity between
glutamate metabolism and synaptic activity10, as well as our own data, it may be
that nNOS-derived protein S-nitrosylation contributes to the synapse-pruning
events underlying the developmental transition between the juvenile and adult
brain45-46. Mechanistically, this may be accomplished by facilitating spatially
restricted elevations of extracellular glutamate to strengthen specific synapses,
while weakening others by allowing astrocytic glutamate removal and
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subsequent oxidation. Additionally, alterations in these events could play a role
in aberrant neurological disorders such as schizophrenia, autism spectrum
disorder (ASD), and epilepsy due to changes in nNOS expression and its
associated synthesis of ˙NO47-51. The study of these processes in a
developmental context is worthy of further inquiry, and may lead to novel
therapeutic avenues for specific diseases in the CNS.
Several forms of neurodegeneration exhibit evidence of glutamatedependent excitotoxicity, including Alzheimer’s disease52 (AD), Parkinson’s
disease53 (PD), stroke54, and traumatic brain injury55 (TBI). One common
component of pathological progression in these diseases is the increased
synthesis of ˙NO by nNOS, which in some cases is subsequently followed by the
S-nitrosylation of specific proteins that contribute to cell death56. In particular,
genetic deletion or inhibition of nNOS in rodents is neuroprotective following
cerebral ischemia, MPTP treatment, or TBI11,57-61. Our results may provide an
explanation for this effect, by implicating nNOS-derived protein S-nitrosylation in
generating the excessive synaptic glutamate concentrations necessary for
downstream excitotoxic events. If this is the case, one way to potentially
ameliorate these deleterious effects is to administer branched-chain amino acids
(BCAAs): these supplements can allosterically activate glutamate
dehydrogenase62, leading to increased glutamate oxidation and, as a corollary,
decreased glutamate availability for excitotoxic processes. BCAA administration
has already been shown promote cognitive rehabilitation after TBI in rodents63-64,
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and may promote a similar recovery following ischemia or other forms of
neurodegeneration. However, the perturbation of this pathway under such
conditions needs to be confirmed before alternative therapeutic options are
considered.
The data presented in this work provides compelling evidence for nNOSderived protein S-nitrosylation in the regulation of synaptic glutamate levels
during normal function in the CNS. By extending its findings to additional
physiological and non-physiological paradigms, we can ask more detailed
questions about the functional relevance in synaptic activity, as well as whether
aberrant ˙NO-dependent regulation of glutamate metabolism plays a role in the
pathological progression of different neurological disorders. Furthermore, in
doing so we can explore opportunities for therapeutic intervention that focus on
either nNOS (as has been done for ischemia65) or specific steps of
glutamate/glutamine metabolism.
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